Document:

EX-4.2

 Exhibit 4.2 

Execution Version 
  

 
 PLIANT THERAPEUTICS, INC.

 AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

December 19, 2019 

 AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

THIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of the 19th day
of December, 2019, by and among PLIANT THERAPEUTICS, INC., a Delaware corporation (the “Company”), and each of the investors listed on Schedule A hereto, (together with
any subsequent investors who become parties hereto as “Investors” in accordance with Section 6.9 hereto, collectively, the “Investors”). 

RECITALS 

WHEREAS, the Company and certain of the Investors are parties to the Series C Preferred Stock Purchase Agreement of even date herewith
(the “Purchase Agreement”); 
 WHEREAS, certain of the Investors (the “Prior
Investors”) are parties to that certain Investors’ Rights Agreement dated as of July 10, 2018, by and among the Company and the Prior Investors (as amended, the “Prior Agreement”); 

WHEREAS, Subsection 6.6 of the Prior Agreement provides that the Prior Agreement may be amended with the written consent of
(a) the Company and (b) the holders of a majority of the Registrable Securities (as defined in the Prior Agreement) then outstanding (collectively, the “Amending Parties”); 

WHEREAS, the undersigned Amending Parties desire to amend and restate the Prior Agreement and accept on behalf of all of the parties
hereto the rights and covenants hereof in lieu of such parties’ rights and covenants under the Prior Agreement; and 
 WHEREAS,
in order to induce the Company to enter into the Purchase Agreement and to induce the Investors to invest funds in the Company pursuant to the Purchase Agreement, the Investors and the Company hereby agree that this Agreement shall govern the rights
of the Investors to cause the Company to register shares of Common Stock (as defined below) issuable to the Investors, to receive certain information from the Company, and to participate in future equity offerings by the Company, and shall govern
certain other matters as set forth in this Agreement; 
 NOW, THEREFORE, the parties hereby agree as follows: 

 

	 	1.	 Definitions. For purposes of this Agreement: 

1.1 “Affiliate” means, with respect to any specified Person, any other Person who, directly or
indirectly, controls, is controlled by, or is under common control with such Person, including, without limitation, any general partner, managing member, officer or director of such Person or any venture capital fund or registered investment company
now or hereafter existing that is controlled by one or more general partners, managing members or investment advisers of, or shares the same management company or investment adviser with, such Person. 

 1.2 “Certificate of Incorporation” means the
Company’s current certificate of incorporation, as amended from time to time. 
 1.3 “Common
Stock” means shares of the Company’s common stock, par value $0.0001 per share. 
 1.4
“Damages” means any loss, damage, claim or liability (joint or several) to which a party hereto may become subject under the Securities Act, the Exchange Act, or other federal or state law, insofar as such loss, damage, claim
or liability (or any action in respect thereof) arises out of or is based upon: (i) any untrue statement or alleged untrue statement of a material fact contained in any registration statement of the Company, including any preliminary prospectus
or final prospectus contained therein or any amendments or supplements thereto; (ii) an omission or alleged omission to state therein a material fact required to be stated therein, or necessary to make the statements therein not misleading; or
(iii) any violation or alleged violation by the indemnifying party (or any of its agents or Affiliates) of the Securities Act, the Exchange Act, any state securities law, or any rule or regulation promulgated under the Securities Act, the
Exchange Act, or any state securities law. 
 1.5 “Derivative Securities” means any securities
or rights convertible into, or exercisable or exchangeable for (in each case, directly or indirectly), Common Stock, including options and warrants. 

1.6 “Exchange Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations
promulgated thereunder. 
 1.7 “Excluded Registration” means (i) a registration relating to the
sale of securities to employees of the Company or a subsidiary pursuant to a stock option, stock purchase, or similar plan; (ii) a registration relating to an SEC Rule 145 transaction; (iii) a registration on any form that does not
include substantially the same information as would be required to be included in a registration statement covering the sale of the Registrable Securities; or (iv) a registration in which the only Common Stock being registered is Common Stock
issuable upon conversion of debt securities that are also being registered. 
 1.8
“Form S-1” means such form under the Securities Act as in effect on the date hereof or any successor registration form under the
Securities Act subsequently adopted by the SEC. 
 1.9 “Form S-3” means such form under the Securities Act as in effect on the date hereof or any registration form under the Securities Act subsequently adopted by the SEC that permits incorporation of substantial
information by reference to other documents filed by the Company with the SEC. 
 1.10 “GAAP” means
generally accepted accounting principles in the United States, as in effect from time to time. 

  
 3 

 1.11 “Holder” means any holder of Registrable
Securities who is a party to this Agreement. 
 1.12 “Immediate Family Member” means a child,
stepchild, grandchild, parent, stepparent, grandparent, spouse, sibling, mother-in-law,
father-in-law, son-in-law, daughter-in-law, brother-in-law, or
sister-in-law, including, adoptive relationships, of a natural person referred to herein. 

1.13 “Initiating Holders” means, collectively, Holders who properly initiate a registration request
under this Agreement. 
 1.14 “IPO” means the Company’s first underwritten public offering of
its Common Stock under the Securities Act. 
 1.15 “Key Employee” means any executive-level employee
(including, division director and vice president-level positions) as well as any employee who, either alone or in concert with others, develops, invents, programs, or designs any Company Intellectual Property (as defined in the Purchase Agreement).

 1.16 “Major Investor” means any Investor that, individually or together with such Investor’s
Affiliates, holds at least 1,089,561 shares of Registrable Securities (as adjusted for any stock split, stock dividend, combination, or other recapitalization or reclassification effected after the date hereof). 

1.17 “New Securities” means, collectively, equity securities of the Company, whether or not currently
authorized, as well as rights, options, or warrants to purchase such equity securities, or securities of any type whatsoever that are, or may become, convertible or exchangeable into or exercisable for such equity securities. 

1.18 “Person” means any individual, corporation, partnership, trust, limited liability company,
association or other entity. 
 1.19 “Preferred Stock” means, collectively, the Series A Preferred
Stock, the Series B Preferred Stock and the Series C Preferred Stock. 
 1.20 “Registrable
Securities” means (i) the Common Stock issuable or issued upon conversion of the Preferred Stock; (ii) any Common Stock, or any Common Stock issued or issuable (directly or indirectly) upon conversion, exercise of any
other securities of the Company or both, acquired by the Investors after the date hereof; (iii) any Common Stock issued as (or issuable upon the conversion or exercise of any warrant, right, or other security that is issued as) a dividend or
other distribution with respect to, or in exchange for or in replacement of, the shares referenced in clauses (i) and (ii) above; excluding in all cases, however, any Registrable Securities sold by a Person in a transaction in which the
applicable rights under this Agreement are not assigned pursuant to Subsection 6.1, and excluding for purposes of Section 2 any shares for which registration rights have terminated pursuant to Subsection 2.13
of this Agreement. 

  
 4 

 1.21 “Registrable Securities then outstanding” means
the number of shares determined by adding the number of shares of outstanding Common Stock that are Registrable Securities and the number of shares of Common Stock issuable (directly or indirectly) pursuant to then exercisable and/or convertible
securities that are Registrable Securities. 
 1.22 “Restricted Securities” means the securities of
the Company required to be notated with the legend set forth in Subsection 2.12(b) hereof. 
 1.23
“SEC” means the Securities and Exchange Commission. 
 1.24 “SEC
Rule 144” means Rule 144 promulgated by the SEC under the Securities Act. 

1.25 “SEC Rule 145” means Rule 145 promulgated by the SEC under
the Securities Act. 
 1.26 “Securities Act” means the Securities Act of 1933, as amended, and the
rules and regulations promulgated thereunder. 
 1.27 “Selling Expenses” means all underwriting
discounts, selling commissions, and stock transfer taxes applicable to the sale of Registrable Securities, and fees and disbursements of counsel for any Holder, except for the fees and disbursements of the Selling Holder Counsel borne and paid by
the Company as provided in Subsection 2.6. 
 1.28
“Series A Preferred Stock” means shares of the Company’s Series A Preferred Stock, par value $0.0001 per share. 

1.29 “Series B Preferred Stock” means shares of the Company’s Series B Preferred Stock, par value
$0.0001 per share. 
 1.30 “Series C Preferred Stock” means shares of the Company’s Series C
Preferred Stock, par value $0.0001 per share. 
  

	 	2.	 Registration Rights. The Company covenants and agrees as follows: 

2.1 Demand Registration. 

(a) Form S-1 Demand. If at any time after the earlier of
(i) five (5) years after the date of the execution of the Prior Agreement or (ii) one hundred eighty (180) days after the effective date of the registration statement for the IPO, the Company receives a request from Holders of a
majority of the Registrable Securities then outstanding that the Company file a Form S-1 registration statement with respect to at least forty percent (40%) of the Registrable Securities then outstanding,
then the Company shall (x) within ten (10) days after the date such request is given, give notice thereof (the “Demand Notice”) to all Holders other than the Initiating Holders; and (y) as soon as practicable,
and in any event within sixty (60) days after the date such request is given by the Initiating Holders, file a Form S-1 registration statement 

  
 5 

 
under the Securities Act covering all Registrable Securities that the Initiating Holders requested to be registered and any additional Registrable Securities requested to be included in such
registration by any other Holders, as specified by notice given by each such Holder to the Company within twenty (20) days of the date the Demand Notice is given, and in each case, subject to the limitations of
Subsections 2.1(c) and 2.3. 
 (b)
Form S-3 Demand. If at any time when it is eligible to use a Form S-3 registration statement, the Company receives a request from
Holders of at least twenty percent (20%) of the Registrable Securities then outstanding that the Company file a Form S-3 registration statement with respect to outstanding Registrable Securities of such
Holders having an anticipated aggregate offering price, net of Selling Expenses, of at least $5.0 million, then the Company shall (i) within ten (10) days after the date such request is given, give a Demand Notice to all Holders other
than the Initiating Holders; and (ii) as soon as practicable, and in any event within forty-five (45) days after the date such request is given by the Initiating Holders, file a Form S-3
registration statement under the Securities Act covering all Registrable Securities requested to be included in such registration by any other Holders, as specified by notice given by each such Holder to the Company within twenty (20) days of
the date the Demand Notice is given, and in each case, subject to the limitations of Subsections 2.1(c) and 2.3. 
 (c)
Notwithstanding the foregoing obligations, if the Company furnishes to Holders requesting a registration pursuant to this Subsection 2.1 a certificate signed by the Company’s chief executive officer stating that in the good faith
judgment of the Company’s Board of Directors it would be materially detrimental to the Company and its stockholders for such registration statement to either become effective or remain effective for as long as such registration statement
otherwise would be required to remain effective, because such action would (i) materially interfere with a significant acquisition, corporate reorganization, or other similar transaction involving the Company; (ii) require premature
disclosure of material information that the Company has a bona fide business purpose for preserving as confidential; or (iii) render the Company unable to comply with requirements under the Securities Act or Exchange
Act, then the Company shall have the right to defer taking action with respect to such filing, and any time periods with respect to filing or effectiveness thereof shall be tolled correspondingly, for a period of not more than ninety (90) days
after the request of the Initiating Holders is given; provided, however, that the Company may not invoke this right more than once in any twelve (12) month period; and provided further that the Company shall not
register any securities for its own account or that of any other stockholder during such ninety (90) day period other than pursuant to a registration relating to the sale of securities to employees of the Company or a subsidiary pursuant to a
stock option, stock purchase, or similar plan; a registration on any form that does not include substantially the same information as would be required to be included in a registration statement covering the sale of the Registrable Securities; or a
registration in which the only Common Stock being registered is Common Stock issuable upon conversion of debt securities that are also being registered. 

(d) The Company shall not be obligated to effect, or to take any action to effect, any registration pursuant to Subsection 2.1(a)(i)
during the period that is sixty (60) days before the Company’s good faith estimate of the date of filing of, and ending on a date that is one hundred eighty (180) days after the effective date of, a Company-initiated registration,
provided that the Company is actively employing in good faith commercially reasonable efforts to cause 

  
 6 

 
such registration statement to become effective; (ii) after the Company has effected two registrations pursuant to Subsection 2.1(a); or (iii) if the Initiating Holders propose
to dispose of shares of Registrable Securities that may be immediately registered on Form S-3 pursuant to a request made pursuant to Subsection 2.1(b). The Company shall not be
obligated to effect, or to take any action to effect, any registration pursuant to Subsection 2.1(b) (i) during the period that is thirty (30) days before the Company’s good faith estimate of the date of filing of, and ending
on a date that is ninety (90) days after the effective date of, a Company-initiated registration, provided that the Company is actively employing in good faith commercially reasonable efforts to cause such registration statement to
become effective; or (ii) if the Company has effected two registrations pursuant to Subsection 2.1(b) within the twelve (12) month period immediately preceding the date of such request. A registration shall not be counted as
“effected” for purposes of this Subsection 2.1(d) until such time as the applicable registration statement has been declared effective by the SEC, unless the Initiating Holders withdraw their request for such
registration, elect not to pay the registration expenses therefor, and forfeit their right to one demand registration statement pursuant to Subsection 2.6, in which case such withdrawn registration statement shall be
counted as “effected” for purposes of this Subsection 2.1(d). 
 2.2 Company Registration. If the Company proposes to
register (including, for this purpose, a registration effected by the Company for stockholders other than the Holders) any of its securities under the Securities Act in connection with the public offering of such securities solely for cash (other
than in an Excluded Registration), the Company shall, at such time, promptly give each Holder notice of such registration. Upon the request of each Holder given within twenty (20) days after such notice is given by the Company, the Company
shall, subject to the provisions of Subsection 2.3, cause to be registered all of the Registrable Securities that each such Holder has requested to be included in such registration. The Company shall have the right to terminate or withdraw
any registration initiated by it under this Subsection 2.2 before the effective date of such registration, whether or not any Holder has elected to include Registrable Securities in such registration. The expenses (other than Selling
Expenses) of such withdrawn registration shall be borne by the Company in accordance with Subsection 2.6. 
 2.3 Underwriting
Requirements. 
 (a) If, pursuant to Subsection 2.1, the Initiating Holders intend to distribute the Registrable Securities
covered by their request by means of an underwriting, they shall so advise the Company as a part of their request made pursuant to Subsection 2.1, and the Company shall include such information in the Demand Notice. The
underwriter(s) will be selected by the Company and shall be reasonably acceptable to a majority in interest of the Initiating Holders. In such event, the right of any Holder to include such Holder’s Registrable Securities in such registration
shall be conditioned upon such Holder’s participation in such underwriting and the inclusion of such Holder’s Registrable Securities in the underwriting to the extent provided herein. All Holders proposing to distribute their securities
through such underwriting shall (together with the Company as provided in Subsection 2.4(e)) enter into an underwriting agreement in customary form with the underwriter(s) selected for such underwriting. Notwithstanding any other provision of
this Subsection 2.3, if the managing underwriter(s) advise(s) the Initiating Holders in writing that marketing factors require a limitation on the number of shares to be underwritten, then the Initiating Holders shall so advise all Holders of
Registrable Securities that otherwise would be underwritten pursuant hereto, and the number of 

  
 7 

 
Registrable Securities that may be included in the underwriting shall be allocated among such Holders of Registrable Securities, including the Initiating Holders, in proportion (as nearly as
practicable) to the number of Registrable Securities owned by each Holder or in such other proportion as shall mutually be agreed to by all such selling Holders; provided, however, that the number of Registrable Securities held by the
Holders to be included in such underwriting shall not be reduced unless all other securities are first entirely excluded from the underwriting. To facilitate the allocation of shares in accordance with the above provisions, the Company or the
underwriters may round the number of shares allocated to any Holder to the nearest one hundred (100) shares. 
 (b) In connection with
any offering involving an underwriting of shares of the Company’s capital stock pursuant to Subsection 2.2, the Company shall not be required to include any of the Holders’ Registrable Securities in such underwriting unless the
Holders accept the terms of the underwriting as agreed upon between the Company and its underwriters, and then only in such quantity as the underwriters in their sole discretion determine will not jeopardize the success of the offering by the
Company. If the total number of securities, including Registrable Securities, requested by stockholders to be included in such offering exceeds the number of securities to be sold (other than by the Company) that the underwriters in their reasonable
discretion determine is compatible with the success of the offering, then the Company shall be required to include in the offering only that number of such securities, including Registrable Securities, which the underwriters and the Company in their
sole discretion determine will not jeopardize the success of the offering. If the underwriters determine that less than all of the Registrable Securities requested to be registered can be included in such offering, then the Registrable Securities
that are included in such offering shall be allocated among the selling Holders in proportion (as nearly as practicable to) the number of Registrable Securities owned by each selling Holder or in such other proportions as shall mutually be agreed to
by all such selling Holders. To facilitate the allocation of shares in accordance with the above provisions, the Company or the underwriters may round the number of shares allocated to any Holder to the nearest one hundred (100) shares.
Notwithstanding the foregoing, in no event shall (i) the number of Registrable Securities included in the offering be reduced unless all other securities (other than securities to be sold by the Company) are first entirely excluded from the
offering, or (ii) the number of Registrable Securities included in the offering be reduced below twenty percent (20%) of the total number of securities included in such offering, unless such offering is the IPO, in which case the selling
Holders may be excluded further if the underwriters make the determination described above and no other stockholder’s securities are included in such offering. For purposes of the provision in this Subsection 2.3(b) concerning
apportionment, for any selling Holder that is a partnership, limited liability company, or corporation, the partners, members, retired partners, retired members, stockholders, and Affiliates of such Holder, or the estates and Immediate Family
Members of any such partners, retired partners, members, and retired members and any trusts for the benefit of any of the foregoing Persons, shall be deemed to be a single “selling Holder,” and any pro rata
reduction with respect to such “selling Holder” shall be based upon the aggregate number of Registrable Securities owned by all Persons included in such “selling Holder,” as defined in this sentence. 

  
 8 

 (c) For purposes of Subsection 2.1, a registration shall not be counted as
“effected” if, as a result of an exercise of the underwriter’s cutback provisions in Subsection 2.3(a), fewer than fifty percent (50%) of the total number of Registrable Securities that Holders have requested to be
included in such registration statement are actually included. 
 2.4 Obligations of the Company. Whenever required under this
Section 2 to effect the registration of any Registrable Securities, the Company shall, as expeditiously as reasonably possible: 

(a) prepare and file with the SEC a registration statement with respect to such Registrable Securities and use its commercially reasonable
efforts to cause such registration statement to become effective and, upon the request of the Holders of a majority of the Registrable Securities registered thereunder, keep such registration statement effective for a period of up to one hundred
twenty (120) days or, if earlier, until the distribution contemplated in the registration statement has been completed; provided, however, that (i) such one hundred twenty (120) day period shall be extended for a period
of time equal to the period the Holder refrains, at the request of an underwriter of Common Stock (or other securities) of the Company, from selling any securities included in such registration, and (ii) in the case of any registration of
Registrable Securities on Form S-3 that are intended to be offered on a continuous or delayed basis, subject to compliance with applicable SEC rules, such one hundred twenty (120) day period shall be
extended for up to one hundred twenty (120) days, if necessary, to keep the registration statement effective until all such Registrable Securities are sold; 

(b) prepare and file with the SEC such amendments and supplements to such registration statement, and the prospectus used in connection with
such registration statement, as may be necessary to comply with the Securities Act in order to enable the disposition of all securities covered by such registration statement; 

(c) furnish to the selling Holders such numbers of copies of a prospectus, including a preliminary prospectus, as required by the Securities
Act, and such other documents as the Holders may reasonably request in order to facilitate their disposition of their Registrable Securities; 

(d) use its commercially reasonable efforts to register and qualify the securities covered by such registration statement under such other
securities or blue-sky laws of such jurisdictions as shall be reasonably requested by the selling Holders; provided that the Company shall not be required to qualify to do business or to file a general
consent to service of process in any such states or jurisdictions, unless the Company is already subject to service in such jurisdiction and except as may be required by the Securities Act; 

(e) in the event of any underwritten public offering, enter into and perform its obligations under an underwriting agreement, in usual and
customary form, with the underwriter(s) of such offering; 
 (f) use its commercially reasonable efforts to cause all such Registrable
Securities covered by such registration statement to be listed on a national securities exchange or trading system and each securities exchange and trading system (if any) on which similar securities issued by the Company are then listed; 

  
 9 

 (g) provide a transfer agent and registrar for all Registrable Securities registered
pursuant to this Agreement and provide a CUSIP number for all such Registrable Securities, in each case not later than the effective date of such registration; 

(h) promptly make available for inspection by the selling Holders, any managing underwriter(s) participating in any disposition pursuant to
such registration statement, and any attorney or accountant or other agent retained by any such underwriter or selected by the selling Holders, all financial and other records, pertinent corporate documents, and properties of the Company, and cause
the Company’s officers, directors, employees, and independent accountants to supply all information reasonably requested by any such seller, underwriter, attorney, accountant, or agent, in each case, as necessary or advisable to verify the
accuracy of the information in such registration statement and to conduct appropriate due diligence in connection therewith; 
 (i) notify
each selling Holder, promptly after the Company receives notice thereof, of the time when such registration statement has been declared effective or a supplement to any prospectus forming a part of such registration statement has been filed; and

 (j) after such registration statement becomes effective, notify each selling Holder of any request by the SEC that the Company amend or
supplement such registration statement or prospectus. 
 In addition, the Company shall ensure that, at all times after any registration
statement covering a public offering of securities of the Company under the Securities Act shall have become effective, its insider trading policy shall provide that the Company’s directors may implement a trading program under Rule 10b5-1 of the Exchange Act. 
 2.5 Furnish Information. It shall be a condition precedent
to the obligations of the Company to take any action pursuant to this Section 2 with respect to the Registrable Securities of any selling Holder that such Holder shall furnish to the Company such information regarding
itself, the Registrable Securities held by it, and the intended method of disposition of such securities as is reasonably required to effect the registration of such Holder’s Registrable Securities. 

2.6 Expenses of Registration. All expenses (other than Selling Expenses) incurred in connection with registrations, filings, or
qualifications pursuant to Section 2, including all registration, filing, and qualification fees; printers’ and accounting fees; fees and disbursements of counsel for the Company; and the reasonable fees and
disbursements, not to exceed $25,000, of one counsel for the selling Holders (“Selling Holder Counsel”), shall be borne and paid by the Company; provided, however, that the Company shall not be required to pay
for any expenses of any registration proceeding begun pursuant to Subsection 2.1 if the registration request is subsequently withdrawn at the request of the Holders of a majority of the Registrable Securities to be registered (in which case
all selling Holders shall bear such expenses pro rata based upon the number of Registrable Securities that were to be included in the withdrawn registration), unless the Holders of a majority of the Registrable Securities
agree to forfeit their right to one registration pursuant to Subsections 2.1(a) or 2.1(b), as the case may be; provided further that if, at the time of such withdrawal, the Holders shall have learned of a

  
 10 

 
material adverse change in the condition, business, or prospects of the Company from that known to the Holders at the time of their request and have withdrawn the request with reasonable
promptness after learning of such information then the Holders shall not be required to pay any of such expenses and shall not forfeit their right to one registration pursuant to Subsections 2.1(a) or 2.1(b). All Selling Expenses
relating to Registrable Securities registered pursuant to this Section 2 shall be borne and paid by the Holders pro rata on the basis of the number of Registrable Securities registered on their
behalf. 
 2.7 Delay of Registration. No Holder shall have any right to obtain or seek an injunction restraining or otherwise delaying
any registration pursuant to this Agreement as the result of any controversy that might arise with respect to the interpretation or implementation of this Section 2. 

2.8 Indemnification. If any Registrable Securities are included in a registration statement under this
Section 2: 
 (a) To the extent permitted by law, the Company will indemnify and hold harmless each selling Holder,
and the partners, members, officers, directors, and stockholders of each such Holder; legal counsel and accountants for each such Holder; any underwriter (as defined in the Securities Act) for each such Holder; and each Person, if any, who controls
such Holder or underwriter within the meaning of the Securities Act or the Exchange Act, against any Damages, and the Company will pay to each such Holder, underwriter, controlling Person, or other aforementioned Person any legal or other expenses
reasonably incurred thereby in connection with investigating or defending any claim or proceeding from which Damages may result, as such expenses are incurred; provided, however, that the indemnity agreement contained in this
Subsection 2.8(a) shall not apply to amounts paid in settlement of any such claim or proceeding if such settlement is effected without the consent of the Company, which consent shall not be unreasonably withheld, nor shall the Company be
liable for any Damages to the extent that they arise out of or are based upon actions or omissions made in reliance upon and in conformity with written information furnished by or on behalf of any such Holder, underwriter, controlling Person, or
other aforementioned Person expressly for use in connection with such registration. 
 (b) To the extent permitted by law, each selling
Holder, severally and not jointly, will indemnify and hold harmless the Company, and each of its directors, each of its officers who has signed the registration statement, each Person (if any), who controls the Company within the meaning of the
Securities Act, legal counsel and accountants for the Company, any underwriter (as defined in the Securities Act), any other Holder selling securities in such registration statement, and any controlling Person of any such underwriter or other
Holder, against any Damages, in each case only to the extent that such Damages arise out of or are based upon actions or omissions made in reliance upon and in conformity with written information furnished by or on behalf of such selling Holder
expressly for use in connection with such registration; and each such selling Holder will pay to the Company and each other aforementioned Person any legal or other expenses reasonably incurred thereby in connection with investigating or defending
any claim or proceeding from which Damages may result, as such expenses are incurred; provided, however, that the indemnity agreement contained in this Subsection 2.8(b) shall not apply to amounts paid in settlement of any such
claim or proceeding 

  
 11 

 
if such settlement is effected without the consent of the Holder, which consent shall not be unreasonably withheld; and provided further that in no event shall the aggregate amounts
payable by any Holder by way of indemnity or contribution under Subsections 2.8(b) and 2.8(d) exceed the proceeds from the offering received by such Holder (net of any Selling Expenses paid by such Holder), except in the case of fraud
or willful misconduct by such Holder. 
 (c) Promptly after receipt by an indemnified party under this
Subsection 2.8 of notice of the commencement of any action (including any governmental action) for which a party may be entitled to indemnification hereunder, such indemnified party will, if a claim in respect thereof is to
be made against any indemnifying party under this Subsection 2.8, give the indemnifying party notice of the commencement thereof. The indemnifying party shall have the right to participate in such action and, to the extent the indemnifying
party so desires, participate jointly with any other indemnifying party to which notice has been given, and to assume the defense thereof with counsel mutually satisfactory to the parties; provided, however, that an indemnified party
(together with all other indemnified parties that may be represented without conflict by one counsel) shall have the right to retain one separate counsel, with the fees and expenses to be paid by the indemnifying party, if representation of such
indemnified party by the counsel retained by the indemnifying party would be inappropriate due to actual or potential differing interests between such indemnified party and any other party represented by such counsel in such action. The failure to
give notice to the indemnifying party within a reasonable time of the commencement of any such action shall relieve such indemnifying party of any liability to the indemnified party under this Subsection 2.8, to the extent that such failure
materially prejudices the indemnifying party’s ability to defend such action. The failure to give notice to the indemnifying party will not relieve it of any liability that it may have to any indemnified party otherwise than under this
Subsection 2.8. 
 (d) To provide for just and equitable contribution to joint liability under the Securities Act in any case in which
either: (i) any party otherwise entitled to indemnification hereunder makes a claim for indemnification pursuant to this Subsection 2.8 but it is judicially determined (by the entry of a final judgment or decree by a
court of competent jurisdiction and the expiration of time to appeal or the denial of the last right of appeal) that such indemnification may not be enforced in such case, notwithstanding the fact that this Subsection 2.8 provides for
indemnification in such case, or (ii) contribution under the Securities Act may be required on the part of any party hereto for which indemnification is provided under this Subsection 2.8, then, and in each such case, such parties will
contribute to the aggregate losses, claims, damages, liabilities, or expenses to which they may be subject (after contribution from others) in such proportion as is appropriate to reflect the relative fault of each of the indemnifying party and the
indemnified party in connection with the statements, omissions, or other actions that resulted in such loss, claim, damage, liability, or expense, as well as to reflect any other relevant equitable considerations. The relative fault of the
indemnifying party and of the indemnified party shall be determined by reference to, among other things, whether the untrue or allegedly untrue statement of a material fact, or the omission or alleged omission of a material fact, relates to
information supplied by the indemnifying party or by the indemnified party and the parties’ relative intent, knowledge, access to information, and opportunity to correct or prevent such statement or omission; provided, however,
that, in any such case (x) no Holder will be required to contribute any amount in excess of the public offering price of all such Registrable Securities offered and sold by such Holder pursuant to such registration statement, and (y) no
Person guilty of 

  
 12 

 
fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) will be entitled to contribution from any Person who was not guilty of such fraudulent
misrepresentation; and provided further that in no event shall a Holder’s liability pursuant to this Subsection 2.8(d), when combined with the amounts paid or payable by such Holder pursuant to Subsection 2.8(b),
exceed the proceeds from the offering received by such Holder (net of any Selling Expenses paid by such Holder), except in the case of willful misconduct or fraud by such Holder. 

(e) Unless otherwise superseded by an underwriting agreement entered into in connection with the underwritten public offering, the obligations
of the Company and Holders under this Subsection 2.8 shall survive the completion of any offering of Registrable Securities in a registration under this Section 2, and otherwise shall survive the termination of this
Agreement. 
 2.9 Reports Under Exchange Act. With a view to making available to the Holders the benefits of SEC Rule 144 and any
other rule or regulation of the SEC that may at any time permit a Holder to sell securities of the Company to the public without registration or pursuant to a registration on Form S-3, the Company shall:

 (a) make and keep available adequate current public information, as those terms are understood and defined in SEC Rule 144, at all
times after the effective date of the registration statement filed by the Company for the IPO; 
 (b) use commercially reasonable efforts to
file with the SEC in a timely manner all reports and other documents required of the Company under the Securities Act and the Exchange Act (at any time after the Company has become subject to such reporting requirements); and 

(c) furnish to any Holder, so long as the Holder owns any Registrable Securities, forthwith upon request (i) to the extent accurate, a
written statement by the Company that it has complied with the reporting requirements of SEC Rule 144 (at any time after ninety (90) days after the effective date of the registration statement filed by the Company for the IPO), the
Securities Act, and the Exchange Act (at any time after the Company has become subject to such reporting requirements), or that it qualifies as a registrant whose securities may be resold pursuant to
Form S-3 (at any time after the Company so qualifies); and (ii) such other information as may be reasonably requested in availing any Holder of any rule or regulation of the SEC that permits the
selling of any such securities without registration (at any time after the Company has become subject to the reporting requirements under the Exchange Act) or pursuant to Form S-3 (at any time after the
Company so qualifies to use such form). 
 2.10 Limitations on Subsequent Registration Rights. From and after the date of this
Agreement, the Company shall not, without the prior written consent of the Holders of a majority of the Registrable Securities then outstanding, enter into any agreement with any holder or prospective holder of any securities of the Company that
allow such holder or prospective holder (i) to include such securities in any registration unless, under the terms of such agreement, such holder or prospective holder may include such securities in any such registration only to the extent that
the inclusion of such securities will not reduce the number of the Registrable 

  
 13 

 
Securities of the Holders that are included; or (ii) allow such holder or prospective holder to initiate a demand for registration of any securities held by such holder or prospective
holder; provided that this limitation shall not apply to any additional Investor who becomes a party to this Agreement in accordance with Subsection 6.9. 

2.11 “Market Stand-off” Agreement. Each Holder hereby agrees that it will not, without
the prior written consent of the managing underwriter, during the period ending on the date specified by the Company and the managing underwriter (such period not to exceed one hundred eighty (180) days following the effective date of the
Company’s first firm commitment underwritten public offering of its Common Stock registered under the Securities Act, (i) lend; offer; pledge; sell; contract to sell; sell any option or contract to purchase; purchase any option or contract
to sell; grant any option, right, or warrant to purchase; or otherwise transfer or dispose of, directly or indirectly, any shares of Common Stock or any securities convertible into or exercisable or exchangeable (directly or indirectly) for Common
Stock held immediately before the effective date of the registration statement for such offering or (ii) enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of
such securities, whether any such transaction described in clause (i) or (ii) above is to be settled by delivery of Common Stock or other securities, in cash, or otherwise. The foregoing provisions of this Subsection 2.11 shall
apply only to the IPO, shall not apply to the sale of any shares to an underwriter pursuant to an underwriting agreement, or the transfer of any shares to any trust for the direct or indirect benefit of the Holder or the immediate family of the
Holder, provided that the trustee of the trust agrees to be bound in writing by the restrictions set forth herein, and provided further that any such transfer shall not involve a disposition for value, and shall be applicable to
the Holders only if all officers and directors are subject to the same restrictions and the Company obtains a similar agreement from all stockholders individually owning more than one percent (1%) of the Company’s outstanding Common Stock
(after giving effect to conversion into Common Stock of all outstanding Preferred Stock). The underwriters in connection with such registration are intended third-party beneficiaries of this Subsection 2.11 and shall have the right, power and
authority to enforce the provisions hereof as though they were a party hereto. Each Holder further agrees to execute such agreements as may be reasonably requested by the underwriters in connection with such registration that are consistent with
this Subsection 2.11 or that are necessary to give further effect thereto. Any discretionary waiver or termination of the restrictions of any or all of such agreements by the Company or the underwriters shall apply pro rata to all Holders
that are subject to such agreements, based on the number of shares subject to such agreements. 
 2.12 Restrictions on Transfer. 

(a) The Preferred Stock and the Registrable Securities shall not be sold, pledged, or otherwise transferred, and the Company shall not
recognize and shall issue stop-transfer instructions to its transfer agent with respect to any such sale, pledge, or transfer, except upon the conditions specified in this Agreement, which conditions are intended to ensure compliance with the
provisions of the Securities Act. A transferring Holder will cause any proposed purchaser, pledgee, or transferee of the Preferred Stock and the Registrable Securities held by such Holder to agree to take and hold such securities subject to the
provisions and upon the conditions specified in this Agreement. 

  
 14 

 (b) Each certificate, instrument, or book entry representing (i) the Preferred Stock,
(ii) the Registrable Securities, and (iii) any other securities issued in respect of the securities referenced in clauses (i) and (ii), upon any stock split, stock dividend, recapitalization, merger, consolidation, or similar event,
shall (unless otherwise permitted by the provisions of Subsection 2.12(c)) be notated with a legend substantially in the following form: 

THE SECURITIES REPRESENTED HEREBY HAVE BEEN ACQUIRED FOR INVESTMENT AND HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933. SUCH SHARES
MAY NOT BE SOLD, PLEDGED, OR TRANSFERRED IN THE ABSENCE OF SUCH REGISTRATION OR A VALID EXEMPTION FROM THE REGISTRATION AND PROSPECTUS DELIVERY REQUIREMENTS OF SAID ACT. 

THE SECURITIES REPRESENTED HEREBY MAY BE TRANSFERRED ONLY IN ACCORDANCE WITH THE TERMS OF AN AGREEMENT BETWEEN THE COMPANY AND THE STOCKHOLDER,
A COPY OF WHICH IS ON FILE WITH THE SECRETARY OF THE COMPANY. 
 The Holders consent to the Company making a notation in its records and
giving instructions to any transfer agent of the Restricted Securities in order to implement the restrictions on transfer set forth in this Subsection 2.12. 

(c) The holder of such Restricted Securities, by acceptance of ownership thereof, agrees to comply in all respects with the provisions of this
Section 2. Before any proposed sale, pledge, or transfer of any Restricted Securities, unless there is in effect a registration statement under the Securities Act covering the proposed transaction, the Holder thereof shall
give notice to the Company of such Holder’s intention to effect such sale, pledge, or transfer. Each such notice shall describe the manner and circumstances of the proposed sale, pledge, or transfer in sufficient detail and, if reasonably
requested by the Company, shall be accompanied at such Holder’s expense by either (i) a written opinion of legal counsel who shall, and whose legal opinion shall, be reasonably satisfactory to the Company, addressed to the Company, to the
effect that the proposed transaction may be effected without registration under the Securities Act; (ii) a “no action” letter from the SEC to the effect that the proposed sale, pledge, or transfer of such Restricted Securities without
registration will not result in a recommendation by the staff of the SEC that action be taken with respect thereto; or (iii) any other evidence reasonably satisfactory to counsel to the Company to the effect that the proposed sale, pledge, or
transfer of the Restricted Securities may be effected without registration under the Securities Act, whereupon the Holder of such Restricted Securities shall be entitled to sell, pledge, or transfer such Restricted Securities in accordance with the
terms of the notice given by the Holder to the Company. The Company will not require such a legal opinion or “no action” letter (x) in any transaction in compliance with SEC Rule 144; or (y) in any transaction in which such
Holder distributes Restricted Securities to an Affiliate of such Holder for no consideration; provided that each transferee agrees in writing to be subject to the terms of this Subsection 2.12. Each certificate, instrument, or book
entry representing the Restricted Securities transferred as above provided shall be notated with, except if such transfer is made pursuant to SEC Rule 144, the appropriate restrictive legend set forth in Subsection 2.12(b), except that
such certificate instrument, or book entry shall not be notated with such restrictive legend if, in the opinion of counsel for such Holder and the Company, such legend is not required in order to establish compliance with any provisions of the
Securities Act. 

  
 15 

 2.13 Termination of Registration Rights. The right of any Holder to request
registration or inclusion of Registrable Securities in any registration pursuant to Subsections 2.1 or 2.2 shall terminate upon the earliest to occur of: 

(a) the closing of a Deemed Liquidation Event, as such term is defined in the Company’s Certificate of Incorporation; 

(b) such time as Rule 144 or another similar exemption under the Securities Act is available for the sale of all of such Holder’s
shares without limitation during a three-month period without registration; and 
 (c) the fifth (5th) anniversary of the IPO. 
  

	 	3.	 Information and Observer Rights. 

3.1 Delivery of Financial Statements. So long as a Major Investor (with its Affiliates) shall own not less than 1,089,561 shares of
Registrable Securities (as adjusted for any stock split, stock dividend, combination, or other recapitalization or reclassification effected after the date hereof), the Company shall deliver to each Major Investor, provided that the Board of
Directors has not reasonably determined that such Major Investor is a competitor of the Company (and solely for purposes of this Section 3.1, Novartis shall not be deemed to be a competitor); provided further
that no institutional financial investor may be determined to be a competitor of the Company for any purpose under this Agreement: 
 (a) as
soon as practicable, but in any event within six (6) months (or such longer period approved by the Board of Directors including at least two of the Preferred Directors (as defined in that certain Amended and Restated Voting Agreement of even
date herewith)) after the end of each fiscal year of the Company ending after the date of this Agreement, (i) a balance sheet as of the end of such year, (ii) statements of income and of cash flows for such year, and a comparison between
(x) the actual amounts as of and for such fiscal year and (y) the comparable amounts for the prior year and as included in the Budget (as defined in Subsection 3.1(d)) for such year, with an explanation of any material differences
between such amounts and a schedule as to the sources and applications of funds for such year, and (iii) a statement of stockholders’ equity as of the end of such year, with such financial statements to be audited and certified by
independent public accountants of nationally recognized standing selected by the Company; 
 (b) as soon as practicable, but in any event
within ninety (90) days after the end of each fiscal year of the Company, (i) a balance sheet as of the end of such year, (ii) statements of income and of cash flows for such year, and a comparison between (x) the actual amounts
as of and for such fiscal year and (y) the comparable amounts for the prior year and as included in the Budget (as defined in Subsection 3.1(d)) for such year, and (iii) a statement of stockholders’ equity as of the end of such
year, with such financial statements to be unaudited; 

  
 16 

 (c) as soon as practicable following a request by a Major Investor, but in any event within
forty-five (45) days after the end of each of the first three (3) quarters of each fiscal year of the Company, unaudited statements of income and cash flows for such fiscal quarter, and an unaudited balance sheet as of the end of such
fiscal quarter, all prepared in accordance with GAAP (except that such financial statements may (i) be subject to normal yearend audit adjustments; and (ii) not contain all notes thereto that may be required in accordance with GAAP) or on
a non-GAAP basis consistent with the Company’s past practices; 
 (d) as soon as practicable
following a request by a Major Investor, but in any event thirty (30) days before the end of each fiscal year, a budget for the next fiscal year (collectively, the “Budget”), approved by the Board of Directors and
prepared on a monthly basis, including balance sheets, income statements, and statements of cash flow for such months and, promptly after prepared, any other budgets or revised budgets prepared by the Company; 

(e) as soon as practicable following a request by a Major Investor, but in any event within forty-five (45) days after the end of each
quarter of each fiscal year of the Company, an updated summary capitalization table of the Company; and 
 (f) such other information
relating to the financial condition, business, prospects, or corporate affairs of the Company as any Major Investor may from time to time reasonably request; provided, however, that the Company shall not be obligated under this
Subsection 3.1 to provide information (i) that the Company reasonably determines in good faith to be a trade secret or confidential information (unless covered by an enforceable confidentiality agreement, in a form acceptable to the
Company, it being agreed that Subsection 3.5 shall constitute an enforceable confidentiality agreement in a form acceptable to the Company); or (ii) the disclosure of which would adversely affect the attorney-client privilege between the
Company and its counsel. 
 If, for any period, the Company has any subsidiary whose accounts are consolidated with those of the Company,
then in respect of such period the financial statements delivered pursuant to the foregoing sections shall be the consolidated and consolidating financial statements of the Company and all such consolidated subsidiaries. 

Notwithstanding anything else in this Subsection 3.1 to the contrary, the Company may cease providing the information set forth in this
Subsection 3.1 during the period starting with the date thirty (30) days before the Company’s good-faith estimate of the date of filing of a registration statement if it reasonably concludes it must do so to comply with the SEC
rules applicable to such registration statement and related offering; provided that the Company’s covenants under this Subsection 3.1 shall be reinstated at such time as the Company is no longer actively employing its commercially
reasonable efforts to cause such registration statement to become effective. 
 3.2 Inspection. The Company shall permit each Major
Investor (provided that the Board of Directors has not reasonably determined that such Major Investor is a competitor of the Company; provided further that no institutional financial investor may be determined to be a competitor
of the Company for any purpose under this Agreement), at such Major Investor’s expense, to visit and inspect the Company’s properties; examine its books of account and 

  
 17 

 
records; and discuss the Company’s affairs, finances, and accounts with its officers, during normal business hours of the Company as may be reasonably requested by the Major Investor;
provided, however, that the Company shall not be obligated pursuant to this Subsection 3.2 to provide access to any information that it reasonably and in good faith considers to be a trade secret or confidential information
(unless covered by an enforceable confidentiality agreement, in a form acceptable to the Company) or the disclosure of which would adversely affect the attorney-client privilege between the Company and its counsel. 

3.3 Observer Rights. As long as Novartis Institutes for Biomedical Research, Inc. (“Novartis”) owns not less than fifty
percent (50%) of the shares of the Series C Preferred Stock it is purchasing under the Purchase Agreement (or an equivalent amount of Common Stock issued upon conversion thereof), the Company shall invite a representative of Novartis that is
mutually acceptable to the Company and Novartis to attend all open meetings of the Board of Directors in a nonvoting observer capacity and, in this respect, shall give such representative copies of all notices, minutes, consents, and other materials
that it provides to its directors at the same time and in the same manner as provided to such directors; provided, however, that such representative shall agree to hold in confidence and trust and to act in a fiduciary manner with
respect to all information so provided; provided further, that the Company reserves the right to withhold any information and to exclude such representative from any meeting or portion thereof if access to such information or
attendance at such meeting could (i) adversely affect the attorney-client privilege between the Company and its counsel or (ii) result in disclosure of highly-confidential or sensitive information, trade secrets or a potential or actual
conflict of interest; or if such Investor or its representative is a competitor of the Company; and provided further that the Company reserves the right to exclude such representative from any executive session of the Board of
Directors. 
 3.4 Termination of Information Rights. The covenants set forth in Subsection 3.1,
Subsection 3.2 and Subsection 3.3 shall terminate and be of no further force or effect (i) immediately before the consummation of the IPO, or (ii) upon a Deemed Liquidation Event, as such term is defined in the Company’s
Certificate of Incorporation, whichever event occurs first. 
 3.5 Confidentiality. Each Investor agrees that such Investor will keep
confidential and will not disclose, divulge, or use for any purpose (other than to monitor its investment in the Company) any confidential information obtained from the Company pursuant to the terms of this Agreement (including notice of the
Company’s intention to file a registration statement), unless such confidential information (a) is known or becomes known to the public in general (other than as a result of a breach of this Section 3.4 by such
Investor), (b) is or has been independently developed or conceived by the Investor without use of the Company’s confidential information, or (c) is or has been made known or disclosed to the Investor by a third party without, to such
Investor’s knowledge, a breach of any obligation of confidentiality such third party may have to the Company; provided, however, that an Investor may disclose confidential information (i) to its attorneys, accountants,
consultants, and other professionals to the extent necessary to obtain their services in connection with monitoring its investment in the Company; (ii) to any prospective purchaser of any Registrable Securities from such Investor, if such
prospective purchaser agrees to be bound by the provisions of this Subsection 3.4; (iii) to any existing or prospective Affiliate, partner, member, stockholder, or wholly owned subsidiary of

  
 18 

 
such Investor in the ordinary course of business, provided that such Investor informs such Person that such information is confidential and directs such Person to maintain the
confidentiality of such information; or (iv) as may otherwise be required by law, provided that the Investor promptly notifies the Company of such disclosure and takes reasonable steps to minimize the extent of any such required
disclosure. 
  

	 	4.	 Rights to Future Stock Issuances. 

4.1 Right of First Offer. Subject to the terms and conditions of this Subsection 4.1 and applicable securities
laws, if the Company proposes to offer or sell any New Securities, the Company shall first offer such New Securities to each Major Investor. A Major Investor shall be entitled to apportion the right of first offer hereby granted to it in such
proportions as it deems appropriate, among (i) itself, (ii) its Affiliates and (iii) its beneficial interest holders, such as limited partners, members or any other Person having “beneficial ownership,” as such term is
defined in Rule 13d-3 promulgated under the Exchange Act, of such Major Investor. 
 (a) The
Company shall give notice (the “Offer Notice”) to each Major Investor, stating (i) its bona fide intention to offer such New Securities, (ii) the number of such New Securities to be
offered, and (iii) the price and terms, if any, upon which it proposes to offer such New Securities. 
 (b) By notification to the
Company within twenty (20) days after the Offer Notice is given, each Major Investor may elect to purchase or otherwise acquire, at the price and on the terms specified in the Offer Notice, up to that portion of such New Securities which equals
the proportion that the Common Stock then held by such Major Investor (including all shares of Common Stock then issuable (directly or indirectly) upon conversion and/or exercise, as applicable, of the Preferred Stock and any other Derivative
Securities then held by such Major Investor) bears to the total Common Stock of the Company then outstanding (assuming full conversion and/or exercise, as applicable, of all Preferred Stock and other Derivative Securities). At the expiration of such
twenty (20) day period, the Company shall promptly notify each Major Investor that elects to purchase or acquire all the shares available to it (each, a “Fully Exercising Investor”) of any other Major Investor’s
failure to do likewise. During the ten (10) day period commencing after the Company has given such notice, each Fully Exercising Investor may, by giving notice to the Company, elect to purchase or acquire, in addition to the number of shares
specified above, up to that portion of the New Securities for which Major Investors were entitled to subscribe but that were not subscribed for by the Major Investors which is equal to the proportion that the Common Stock issued and held, or
issuable (directly or indirectly) upon conversion and/or exercise, as applicable, of Preferred Stock and any other Derivative Securities then held, by such Fully Exercising Investor bears to the Common Stock issued and held, or issuable (directly or
indirectly) upon conversion and/or exercise, as applicable, of the Preferred Stock and any other Derivative Securities then held, by all Fully Exercising Investors who wish to purchase such unsubscribed shares. The closing of any sale pursuant to
this Subsection 4.1(b) shall occur within the later of ninety (90) days of the date that the Offer Notice is given and the date of initial sale of New Securities pursuant to Subsection 4.1(c). 

  
 19 

 (c) If all New Securities referred to in the Offer Notice are not elected to be purchased or
acquired as provided in Subsection 4.1(b), the Company may, during the ninety (90) day period following the expiration of the periods provided in Subsection 4.1(b), offer and sell the remaining unsubscribed portion of such New
Securities to any Person or Persons at a price not less than, and upon terms no more favorable to the offeree than, those specified in the Offer Notice. If the Company does not enter into an agreement for the sale of the New Securities within such
period, or if such agreement is not consummated within thirty (30) days of the execution thereof, the right provided hereunder shall be deemed to be revived and such New Securities shall not be offered unless first reoffered to the Major
Investors in accordance with this Subsection 4.1. 
 (d) The right of first offer in this Subsection 4.1 shall not be
applicable to (i) Exempted Securities (as defined in the Company’s Certificate of Incorporation); (ii) shares of Common Stock issued in the IPO; and (iii) the issuance of shares of Series C Preferred Stock pursuant to the
Purchase Agreement. 
 4.2 Termination. The covenants set forth in Subsection 4.1 shall terminate and be of no further force or
effect (i) immediately before the consummation of the IPO, or (ii) upon a Deemed Liquidation Event, as such term is defined in the Company’s Certificate of Incorporation, whichever event occurs first. 

5. Additional Covenants. 

5.1 Insurance. The Company shall use its commercially reasonable efforts to maintain with financially sound and reputable insurers
Directors and Officers liability insurance in an amount and on terms and conditions satisfactory to the Board of Directors until such time as the Board of Directors determines that such insurance should be discontinued. 

5.2 Employee Agreements. The Company will cause each person now or hereafter employed by it or by any subsidiary (or engaged by the
Company or any subsidiary as a consultant/independent contractor) with access to confidential information and/or trade secrets to enter into a nondisclosure and proprietary rights assignment agreement substantially in the form approved by the Board
of Directors. In addition, the Company shall not amend, modify, terminate, waive, or otherwise alter, in whole or in part, any of the above-referenced agreements or any restricted stock agreement between the Company and any employee, without the
consent of the Board of Directors. 
 5.3 Employee Stock. Unless otherwise approved by the Board of Directors, all future employees
and consultants of the Company who purchase, receive options to purchase, or receive awards of shares of the Company’s capital stock (collectively, “Stock Awards”) after the date hereof shall be required to execute
restricted stock or option agreements, as applicable, providing for (i) vesting of shares over a four (4) year period, with the first twenty-five percent (25%) of such shares vesting following twelve (12) months of continued
employment or service, and the remaining shares vesting in equal monthly installments over the following thirty-six (36) months, and (ii) a market stand-off
provision substantially similar to that in Subsection 2.11. In addition, unless otherwise approved by the Board of Directors, the Company shall retain a “right of first refusal” on employee transfers until the Company’s IPO and
shall have the right to repurchase unvested shares. 

  
 20 

	 	5.4	 CFIUS. 

(a) The Company hereby represents, warrants and covenants to each of Novartis and Mauna Kea Limited (“Lyfe”) that, it has not
taken any of the following actions: The design, fabrication, development, testing, production or manufacture of “critical technologies” as defined by 31 C.F.R. § 801.204, as amended. 

(b) Notwithstanding anything to the contrary contained in this Agreement, the Company represents, warrants, and covenants that the Company
shall not (i) provide each of Novartis and Lyfe with any material nonpublic technical information as defined in 31 C.F.R. § 800 that is in the Company’s possession; or (ii) permit any involvement of Novartis or Lyfe, other than
through voting of shares, in substantive decision making of the Company regarding the use, development, acquisition, or release of any “critical technologies” as defined in 31 C.F.R. § 800.209. Each of Novartis and Lyfe hereby waives
any such information or decision making rights to which it may be entitled under this Agreement or otherwise. 
 5.5 Matters Requiring
Investor Director Approval. So long as at least 35,000,000 shares of Preferred Stock are outstanding (subject to appropriate adjustment for stock splits, stock dividends, combinations, and other recapitalizations), the Company hereby covenants
and agrees with each of the Investors that it shall not, without approval of the Board of Directors: 
 (a) make, or permit any subsidiary to
make, any loan or advance to, or own any stock or other securities of, any subsidiary or other corporation, partnership, or other entity unless it is wholly owned by the Company; 

(b) make, or permit any subsidiary to make, any loan or advance to any Person, including, without limitation, any employee or director of the
Company or any subsidiary, except advances and similar expenditures in the ordinary course of business or under the terms of an employee stock or option plan approved by the Board of Directors; 

(c) guarantee, directly or indirectly, or permit any subsidiary to guarantee, directly or indirectly, any indebtedness except for trade
accounts of the Company or any subsidiary arising in the ordinary course of business; 
 (d) make any investment inconsistent with any
investment policy approved by the Board of Directors; 
 (e) incur any aggregate indebtedness in excess of $500,000 that is not already
included in a budget approved by the Board of Directors, other than trade credit incurred in the ordinary course of business; 

  
 21 

 (f) otherwise enter into or be a party to any transaction with any director, officer, or
employee of the Company or any “associate” (as defined in Rule 12b-2 promulgated under the Exchange Act) of any such Person, including without limitation any “management bonus” or
similar plan providing payments to employees in connection with a Deemed Liquidation Event, as such term is defined in the Company’s Certificate of Incorporation, except for transactions contemplated by this Agreement, the Purchase Agreement
and transactions resulting in payments to or by the Company in an aggregate amount less than $60,000 per year; 
 (g) hire, terminate, or
change the compensation of the executive officers, including approving any option grants or stock awards to executive officers; 
 (h) change
the principal business of the Company, enter new lines of business, or exit the current line of business; 
 (i) sell, assign, license,
pledge, or encumber material technology or intellectual property, other than licenses granted in the ordinary course of business; or 
 (j)
enter into any corporate strategic relationship involving the payment, contribution, or assignment by the Company or to the Company of money or assets greater than 500,000. 

5.6 Board Matters. Unless otherwise determined by the vote of a majority of the directors then in office, the Board of Directors shall
meet in accordance with an agreed-upon schedule. The Company shall reimburse the directors for all reasonable out-of-pocket travel expenses incurred (consistent with the
Company’s travel policy) in connection with attending meetings of the Board of Directors. 
 5.7 Successor Indemnification. If
the Company or any of its successors or assignees consolidates with or merges into any other Person and is not the continuing or surviving corporation or entity of such consolidation or merger, then to the extent necessary, proper provision shall be
made so that the successors and assignees of the Company assume the obligations of the Company with respect to indemnification of members of the Board of Directors as in effect immediately before such transaction, whether such obligations are
contained in the Company’s Bylaws, its Certificate of Incorporation, or elsewhere, as the case may be. 
 5.8 Indemnification
Matters. The Company hereby acknowledges that one (1) or more of the directors nominated to serve on the Board of Directors by the Investors (each a “Fund Director”) may have certain rights to indemnification,
advancement of expenses and/or insurance provided by one or more of the Investors and certain of their Affiliates (collectively, the “Fund Indemnitors”). The Company hereby agrees (a) that it is the indemnitor of first
resort (i.e., its obligations to any such Fund Director are primary and any obligation of the Fund Indemnitors to advance expenses or to provide indemnification for the same expenses or liabilities incurred by such Fund Director are
secondary), (b) that it shall be required to advance the full amount of expenses incurred by such Fund Director and shall be liable for the full amount of all expenses, judgments, penalties, fines and amounts paid in settlement by or on behalf
of any such Fund Director to the extent legally permitted and as required by the Company’s Certificate of Incorporation or Bylaws of the Company (or any agreement between the Company and such Fund Director), without regard to any rights such
Fund Director may have against the Fund Indemnitors, and, (c) that it irrevocably waives, relinquishes and releases 

  
 22 

 
the Fund Indemnitors from any and all claims against the Fund Indemnitors for contribution, subrogation or any other recovery of any kind in respect thereof. The Company further agrees that no
advancement or payment by the Fund Indemnitors on behalf of any such Fund Director with respect to any claim for which such Fund Director has sought indemnification from the Company shall affect the foregoing and the Fund Indemnitors shall have a
right of contribution and/or be subrogated to the extent of such advancement or payment to all of the rights of recovery of such Fund Director against the Company. 
  

	 	5.9	 Right to Conduct Activities. 

(a) The Company hereby agrees and acknowledges that Third Rock Ventures III, L.P. (together with its Affiliates, “TRV”)
is a professional investment fund, and as such invests in numerous portfolio companies, some of which may be deemed competitive with the Company’s business (as currently conducted or as currently propose to be conducted). The Company hereby
agrees that, to the extent permitted under applicable law, TRV shall not be liable to the Company for any claim arising out of, or based upon, (i) the investment by TRV in any entity competitive with the Company, or (ii) actions taken by
any partner, officer or other representative of TRV to assist any such competitive company, whether or not such action was taken as a member of the board of directors of such competitive company or otherwise, and whether or not such action has a
detrimental effect on the Company; provided, however, that the foregoing shall not relieve (x) TRV from liability associated with the unauthorized disclosure of the Company’s confidential information obtained pursuant to this
Agreement, or (y) any director or officer of the Company from any liability associated with his or her fiduciary duties to the Company. 

(b) The Company hereby agrees and acknowledges that Cowen Healthcare Investments II LP (together with its Affiliates,
“CHI”) is a professional investment fund, and as such invests in numerous portfolio companies, some of which may be deemed competitive with the Company’s business (as currently conducted or as currently propose to be
conducted). The Company hereby agrees that, to the extent permitted under applicable law, CHI shall not be liable to the Company for any claim arising out of, or based upon, (i) the investment by CHI in any entity competitive with the Company,
or (ii) actions taken by any partner, officer or other representative of CHI to assist any such competitive company, whether or not such action was taken as a member of the board of directors of such competitive company or otherwise, and
whether or not such action has a detrimental effect on the Company; provided, however, that the foregoing shall not relieve (x) CHI from liability associated with the unauthorized disclosure of the Company’s confidential
information obtained pursuant to this Agreement, or (y) any director or officer of the Company from any liability associated with his or her fiduciary duties to the Company. 

(c) The Company hereby agrees and acknowledges that Eventide Gilead Fund and Eventide Healthcare & Life Sciences Fund (together with
their Affiliates, “Eventide”) are professional investment funds, and as such invest in numerous portfolio companies, some of which may be deemed competitive with the Company’s business (as currently conducted or as
currently propose to be conducted). The Company hereby agrees that, to the extent permitted under applicable law, Eventide shall not be liable to the Company for any claim arising out of, or based upon, (i) the investment by Eventide in any
entity competitive with the Company, or 

  
 23 

 
(ii) actions taken by any partner, officer or other representative of Eventide to assist any such competitive company, whether or not such action was taken as a member of the board of
directors of such competitive company or otherwise, and whether or not such action has a detrimental effect on the Company; provided, however, that the foregoing shall not relieve (x) Eventide from liability associated with the
unauthorized disclosure of the Company’s confidential information obtained pursuant to this Agreement, or (y) any director or officer of the Company from any liability associated with his or her fiduciary duties to the Company. 

(d) The Company hereby agrees and acknowledges that Agent Capital Fund I LP (together with its Affiliates, “Agent”) is
a professional investment fund, and as such invests in numerous portfolio companies, some of which may be deemed competitive with the Company’s business (as currently conducted or as currently propose to be conducted). The Company hereby agrees
that, to the extent permitted under applicable law, Agent shall not be liable to the Company for any claim arising out of, or based upon, (i) the investment by Agent in any entity competitive with the Company, or (ii) actions taken by any
partner, officer or other representative of Agent to assist any such competitive company, whether or not such action was taken as a member of the board of directors of such competitive company or otherwise, and whether or not such action has a
detrimental effect on the Company; provided, however, that the foregoing shall not relieve (x) Agent from liability associated with the unauthorized disclosure of the Company’s confidential information obtained pursuant to
this Agreement, or (y) any director or officer of the Company from any liability associated with his or her fiduciary duties to the Company. 

(e) The Company hereby agrees and acknowledges that PH Investments, LLC, SCubed Capital, LLC, Sobrato Capital, Harvard Management Private
Equity Corporation, Fifth Avenue Private Equity 14 LLC, Portland Investment – EP, LLC and Portland Investment – PIA, LLC (together with their respective Affiliates, the “Access Investors”) are professional
investment funds, and as such invest in numerous portfolio companies, some of which may be deemed competitive with the Company’s business (as currently conducted or as currently propose to be conducted). The Company hereby agrees that no Access
Investor shall be determined to be a competitor for purposes of Section 3.1 and 3.2 above and that, to the extent permitted under applicable law, the Access Investors shall not be liable to the Company for any claim arising out of, or based
upon, (i) the investment by any of the Access Investors in any entity competitive with the Company, or (ii) actions taken by any partner, officer or other representative of any Access Investor to assist any such competitive company,
whether or not such action was taken as a member of the board of directors of such competitive company or otherwise, and whether or not such action has a detrimental effect on the Company; provided, however, that the foregoing shall
not relieve (x) any party from liability associated with the unauthorized disclosure of the Company’s confidential information obtained pursuant to this Agreement, or (y) any director or officer of the Company from any liability
associated with his or her fiduciary duties to the Company. 
 (f) The Company hereby agrees and acknowledges that Novartis and its
Affiliates are professional investment funds, and as such invest in numerous portfolio companies, some of which may be deemed competitive with the Company’s business (as currently conducted or as currently propose to be conducted). The Company
hereby agrees that, to the extent permitted under applicable law, neither Novartis nor its Affiliates shall be liable to the 

  
 24 

 
Company for any claim arising out of, or based upon, (i) the investment by Novartis or an Affiliate of Novartis in any entity competitive with the Company, or (ii) actions taken by any
partner, officer or other representative of Novartis or an Affiliate of Novartis to assist any such competitive company, whether or not such action was taken as a member of the board of directors of such competitive company or otherwise, and whether
or not such action has a detrimental effect on the Company; provided, however, that the foregoing shall not relieve (x) Novartis or its Affiliates from liability associated with the unauthorized disclosure of the Company’s
confidential information obtained pursuant to this Agreement, (y) any director or officer of the Company from any liability associated with his or her fiduciary duties to the Company, or (z) any contractual obligations of Novartis or its
Affiliates. 
 5.10 ERISA. The Company will exercise its reasonable best efforts to ensure that, at all times during which any
Investor holds any Preferred Stock or Common Stock, the assets of the Company will not be deemed to be “plan assets” for purposes of the Employee Retirement Income Security Act of 1974, as amended (“ERISA”). The
Company agrees to provide notice, in writing, to each Investor as soon as is reasonably practicable upon determining that the assets of the Company are reasonably likely to be deemed “plan assets” for purposes of ERISA. 

5.11 Publicity. The Company shall not make use of any Access Investor’s name on its website, via press release or other similar
communication without the prior consent of such Access Investor, which consent may be delivered to the Company via email. Notwithstanding the foregoing, the Company may, (i) if an Access Investor’s investment in the Company has been
publicly disclosed by such Access Investor or with such Access Investor’s prior consent, from then forward confirm in non-public communications that such Access Investor has invested in the Company and
provide other information that has been previously disclosed by or with such Access Investor’s consent, and (ii) without the prior approval of an Access Investor, disclose the terms and/or amount of such Access Investor’s investment
and such Access Investor’s identity (x) to an existing Investor, a bona fide potential investor in, or bona fide acquirer or strategic partner of, the Company in connection with such potential party’s due diligence process or
investment (provided that such Access Investor’s identity shall not appear in any slide deck or other similar presentation for or to bona fide potential investors or acquirers) or (y) as required by law, rule, regulation or listing
standard to do so. 
 5.12 Termination of Covenants. The covenants set forth in this Section 5, except for
Subsections 5.6 and 5.7, shall terminate and be of no further force or effect (i) immediately before the consummation of the IPO or (ii) upon a Deemed Liquidation Event, as such term is defined in the Company’s
Certificate of Incorporation, whichever event occurs first. 
  

	 	6.	 Miscellaneous. 

6.1 Successors and Assigns. The rights under this Agreement may be assigned (but only with all related obligations) by a Holder to a
transferee of Registrable Securities that (i) is an Affiliate of a Holder; (ii) is a Holder’s Immediate Family Member or trust for the benefit of an individual Holder or one or more of such Holder’s Immediate Family Members; or
(iii) after such transfer, holds shares of Registrable Securities (subject to appropriate adjustment for stock splits, stock dividends, combinations, and other 

  
 25 

 
recapitalizations); provided, however, that (x) the Company is, within a reasonable time after such transfer, furnished with written notice of the name and address of such
transferee and the Registrable Securities with respect to which such rights are being transferred; and (y) such transferee agrees in a written instrument delivered to the Company to be bound by and subject to the terms and conditions of this
Agreement, including the provisions of Subsection 2.11. For the purposes of determining the number of shares of Registrable Securities held by a transferee, the holdings of a transferee (1) that is an Affiliate or stockholder of a
Holder; (2) who is a Holder’s Immediate Family Member; or (3) that is a trust for the benefit of an individual Holder or such Holder’s Immediate Family Member shall be aggregated together and with those of the transferring
Holder; provided further that all transferees who would not qualify individually for assignment of rights shall have a single attorney-in-fact for the
purpose of exercising any rights, receiving notices, or taking any action under this Agreement. The terms and conditions of this Agreement inure to the benefit of and are binding upon the respective successors and permitted assignees of the parties.
Nothing in this Agreement, express or implied, is intended to confer upon any party other than the parties hereto or their respective successors and permitted assignees any rights, remedies, obligations or liabilities under or by reason of this
Agreement, except as expressly provided herein. 
 6.2 Governing Law. This Agreement shall be governed by the internal law of the
State of California, without regard to conflict of law principles that would result in the application of any law other than the law of the State of California. 

6.3 Counterparts. This Agreement may be executed in two (2) or more counterparts, each of which shall be deemed an original, but
all of which together shall constitute one and the same instrument. Counterparts may be delivered via facsimile, electronic mail (including pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000, e.g.,
www.docusign.com) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes. 

6.4 Titles and Subtitles. The titles and subtitles used in this Agreement are for convenience only and are not to be considered in
construing or interpreting this Agreement. 
 6.5 Notices. All notices and other communications given or made pursuant to this
Agreement shall be in writing and shall be deemed effectively given upon the earlier of actual receipt or (i) personal delivery to the party to be notified; (ii) when sent, if sent by electronic mail or facsimile during the
recipient’s normal business hours, and if not sent during normal business hours, then on the recipient’s next business day; (iii) five (5) days after having been sent by registered or certified mail, return receipt requested,
postage prepaid; or (iv) one (1) business day after the business day of deposit with a nationally recognized overnight courier, freight prepaid, specifying next-day delivery, with written
verification of receipt. All communications shall be sent to the respective parties at their addresses as set forth on Schedule A hereto, or to the principal office of the Company and to the attention
of the Chief Executive Officer, in the case of the Company, or to such email address, facsimile number, or address as subsequently modified by written notice given in accordance with this Subsection 6.5. If notice is given to the Company or
to Stockholders, a copy shall also be sent to Goodwin Procter LLP, 601 Marshall Street, Redwood City, CA 94063, Fax: +1 (650) 853-1038, Attention: Sam Zucker, Esq. and Deepa Rich, Esq. 

  
 26 

 6.6 Amendments and Waivers. Any term of this Agreement may be amended and the
observance of any term of this Agreement may be waived (either generally or in a particular instance, and either retroactively or prospectively) only with the written consent of the Company and the holders of a majority of the Registrable Securities
then outstanding; provided that the Company may in its sole discretion waive compliance with Subsection 2.12(c) (and the Company’s failure to object promptly in writing after notification of a proposed assignment allegedly in
violation of Subsection 2.12(c) shall be deemed to be a waiver); and provided further that any provision hereof may be waived by any waiving party on such party’s own behalf, without the consent of any other party.
Notwithstanding the foregoing, this Agreement may not be amended or terminated and the observance of any term hereof may not be waived with respect to any Investor without the written consent of such Investor, unless such amendment, termination, or
waiver applies to all Investors in the same fashion (it being agreed that a waiver of the provisions of Section 4 with respect to a particular transaction shall be deemed to apply to all Investors in the same fashion if
such waiver does so by its terms, notwithstanding the fact that certain Investors may nonetheless, by agreement with the Company, purchase securities in such transaction). The Company shall give prompt notice of any amendment or termination hereof
or waiver hereunder to any party hereto that did not consent in writing to such amendment, termination, or waiver. Any amendment, termination, or waiver effected in accordance with this Subsection 6.6 shall be binding on all parties hereto,
regardless of whether any such party has consented thereto. No waivers of or exceptions to any term, condition, or provision of this Agreement, in any one or more instances, shall be deemed to be or construed as a further or continuing waiver of any
such term, condition, or provision. 
 6.7 Severability. In case any one or more of the provisions contained in this Agreement is for
any reason held to be invalid, illegal or unenforceable in any respect, such invalidity, illegality, or unenforceability shall not affect any other provision of this Agreement, and such invalid, illegal, or unenforceable provision shall be reformed
and construed so that it will be valid, legal, and enforceable to the maximum extent permitted by law. 
 6.8 Aggregation of Stock.
All shares of Registrable Securities held or acquired by Affiliates shall be aggregated together for the purpose of determining the availability of any rights under this Agreement and such Affiliated persons may apportion such rights as among
themselves in any manner they deem appropriate. 
 6.9 Additional Investors. Notwithstanding anything to the contrary contained
herein, if the Company issues additional shares of Series C Preferred Stock after the date hereof, any purchaser of such shares of Series C Preferred Stock may become a party to this Agreement by executing and delivering an additional counterpart
signature page to this Agreement, and thereafter shall be deemed an “Investor” for all purposes hereunder. 
 6.10 Entire
Agreement. This Agreement (including any Schedules and Exhibits hereto) constitutes the full and entire understanding and agreement among the parties with respect to the subject matter hereof, and any other written or oral agreement
relating to the subject matter hereof existing between the parties is expressly canceled. 

  
 27 

 6.11 Dispute Resolution. The parties (a) hereby irrevocably and unconditionally
submit to the jurisdiction of the state courts of California and to the jurisdiction of the United States District Court for the Northern District of California for the purpose of any suit, action or other proceeding arising out of or based upon
this Agreement, (b) agree not to commence any suit, action or other proceeding arising out of or based upon this Agreement except in the state courts of California or the United States District Court for the Northern District of California, and
(c) hereby waive, and agree not to assert, by way of motion, as a defense, or otherwise, in any such suit, action or proceeding, any claim that it is not subject personally to the jurisdiction of the above-named courts, that its property is
exempt or immune from attachment or execution, that the suit, action or proceeding is brought in an inconvenient forum, that the venue of the suit, action or proceeding is improper or that this Agreement or the subject matter hereof may not be
enforced in or by such court. 
 The prevailing party in any dispute arising under this Agreement shall be entitled to reasonable
attorney’s fees, costs, and necessary disbursements in addition to any other relief to which such party may be entitled. Each of the parties to this Agreement consents to personal jurisdiction for any equitable action sought in the
U.S. District Court for the Northern District of California or any court of the State of California having subject matter jurisdiction. 

6.12 Delays or Omissions. No delay or omission to exercise any right, power, or remedy accruing to any party under this Agreement, upon
any breach or default of any other party under this Agreement, shall impair any such right, power, or remedy of such nonbreaching or nondefaulting party, nor shall it be construed to be a waiver of or acquiescence to any such breach or default, or
to any similar breach or default thereafter occurring, nor shall any waiver of any single breach or default be deemed a waiver of any other breach or default theretofore or thereafter occurring. All remedies, whether under this Agreement or by law
or otherwise afforded to any party, shall be cumulative and not alternative. 
 6.13 Acknowledgment. The Company acknowledges that the
Investors are in the business of venture capital investing and therefore review the business plans and related proprietary information of many enterprises, including enterprises that may have products or services that compete directly or indirectly
with those of the Company. Nothing in this Agreement shall preclude or in any way restrict the Investors from investing or participating in any particular enterprise whether or not such enterprise has products or services that compete with those of
the Company. 
 6.14 Amendment of Prior Agreement. The Prior Agreement is hereby amended and superseded in its entirety and restated
herein. Such amendment and restatement is effective upon the execution of this Agreement by the parties required for an amendment pursuant to Subsection 6.6 of the Prior Agreement. Upon such execution, all provisions of, rights granted and
covenants made in the Prior Agreement are hereby waived, released and superseded in their entirety by the provisions hereof and shall have no further force or effect. 

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

  
 28 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	COMPANY:
	
	PLIANT THERAPEUTICS, INC.
		
	By:	 	 /s/ Bernard Coulie

	Name:	 	Bernard Coulie, M.D., Ph.D.
	Title:	 	President and Chief Executive Officer

 SIGNATURE PAGE TO AMENDED
AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC.
		
	By:	 	 /s/ Scott Brown

	Name:	 	Scott Brown
	Title:	 	VP, Chief Administrative Officer and General Counsel

 Address:   [***] 

  

SIGNATURE PAGE TO AMENDED AND RESTATED
INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	THIRD ROCK VENTURES III, L.P.
	
	By: Third Rock Ventures GP III, L.P., its general partner
	
	By: TRV GP III, LLC, its general partner
		
	By:	 	 /s/ Kevin Gillis

 
			
	Name:	 	Kevin Gillis
	Title:	 	Partner/COO

 Address:   [***] 

 

			
	THIRD ROCK VENTURES IV, L.P.
	
	By: Third Rock Ventures GP IV, L.P., its general partner
	
	By: TRV GP IV, LLC, its general partner
		
	By:	 	 /s/ Kevin Gillis

 
			
	Name:	 	Kevin Gillis
	Title:	 	Partner/COO

 Address:   [***] 

  

SIGNATURE PAGE TO AMENDED AND RESTATED
INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	COWEN HEALTHCARE INVESTMENTS II LP
	
	By: Cowen Healthcare Investments II GP LLC, its General Partner
		
	By:	 	 /s/ Kevin Raidy

	Name:	 	Kevin Raidy
	Title:	 	Managing Partner

 Address:
  [***] 
  

			
	CHI EF II LP
	
	By: Cowen Healthcare Investments II GP LLC, its General Partner
		
	By:	 	 /s/ Kevin Raidy

	Name:	 	Kevin Raidy
	Title:	 	Managing Partner

 Address:   [***] 

  

SIGNATURE PAGE TO AMENDED AND RESTATED
INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

					
		 	INVESTOR:
		
		 	IST3 MANESSE PE L.P.
		
		 	By: IST3 Manesse PE Management L.P., its general partner
		 	By: Schroder Adveq Management Jersey Ltd, its general partner
			
		 	By:	 	 /s/ Mark Nieuwenhuis

		 	Name:	 	Mark Nieuwenhuis
		 	Title:	 	Director
			
		 	By:	 	 /s/ Monika Pinel

		 	Name:	 	Monika Pinel
		 	Title:	 	Authorized Signatory

 Address:   [***] 

  

SIGNATURE PAGE TO AMENDED AND RESTATED
INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

					
		 	INVESTOR:
		
		 	SCHRODER ADVEQ cPl Global 2017-2019 C.V.
		
		 	By: Schroder Adveq cPl Global Management III, L.P., its general partner
		 	By: Schroder Adveq Management N.V., its general partner
			
		 	By:	 	 /s/ Sven Gasser

		 	Name:	 	Sven Gasser
		 	Title:	 	Managing Director
			
		 	By:	 	 /s/ Monika Pinel

		 	Name:	 	Monika Pinel
		 	Title:	 	Proxy Holder

 Address:   [***]

  

					
		 	SCHRODER ADVEQ TECHNOLOGY IX S.C.S.
		 	By: Schroder Adveq Management Luxembourg S.à.r.l. as general partner
			
		 	By:	 	 /s/ Mark Nieuwenhuis

		 	Name:	 	Mark Nieuwenhuis
		 	Title:	 	Authorized Signatory
			
		 	By:	 	 /s/ Monika Pinel

		 	Name:	 	Monika Pinel
		 	Title:	 	Authorized Signatory

 Address:   [***] 

  

SIGNATURE PAGE TO AMENDED AND RESTATED
INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

					
		 	INVESTOR:
		
		 	MENLO VENTURES XIV, L.P.
		
		 	 BY: MV MANAGEMENT XIV, L.L.C.
  

Its General Partner

			
		 	By:	 	 /s/ Greg Yap

		 	Name:	 	Greg Yap
		 	Title:	 	Authorized Signatory

 Address:
  [***] 
  

					
		 	MENLO ENTREPRENEURS FUND XIV, L.P.
		
		 	 BY: MV MANAGEMENT XIV, L.L.C.
  

Its General Partner

			
		 	By:	 	 /s/ Greg Yap

		 	Name:	 	Greg Yap
		 	Title:	 	Authorized Signatory

 Address:
  [***] 
  

					
		 	MMEF XIV, L.P.
		
		 	 BY: MV MANAGEMENT XIV, L.L.C.
  

Its General Partner

			
		 	By:	 	 /s/ Greg Yap

		 	Name:	 	Greg Yap
		 	Title:	 	Authorized Signatory

 Address:   [***] 

  

SIGNATURE PAGE TO AMENDED AND RESTATED
INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

					
		 	INVESTOR:
		
		 	MUTUAL FUND SERIES TRUST, ON BEHALF OF EVENTIDE HEALTHCARE & LIFE SCIENCES FUND
			
		 	By:	 	 /s/ Erik Naviloff

		 	Name:	 	Erik Naviloff
		 	Title:	 	Treasurer

 Address:   [***]

  

					
		 	MUTUAL FUND SERIES TRUST, ON BEHALF OF EVENTIDE GILEAD FUND
			
		 	By:	 	 /s/ Erik Naviloff

		 	Name:	 	Erik Naviloff
		 	Title:	 	Treasurer

 Address:   [***] 

  

SIGNATURE PAGE TO AMENDED AND RESTATED
INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	SCUBED CAPITAL, LLC
		
	By:	 	 /s/ Mark Stevens

	Name:	 	Mark Stevens
	Title:	 	Managing Partner

 Address:   [***] 

With a copy to:   [***] 

  

SIGNATURE PAGE TO AMENDED AND RESTATED
INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	HARVARD MANAGEMENT PRIVATE EQUITY CORPORATION
		
	 By:
	 	 /s/ Elise McDonald

	 Name:
	 	Elise McDonald
	 Title:
	 	Authorized Signatory
		
	 By:
	 	 /s/ Elaine Chan

	 Name:
	 	Elaine Chan
	 Title:
	 	Authorized Signatory

 Address:
  [***] 

  

SIGNATURE PAGE TO AMENDED AND RESTATED
INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	 INVESTOR:

	
	 SOBRATO CAPITAL,

	 a DBA of Sobrato Family Holdings, LLC,

	 a California limited liability company

		
	By:	 	 /s/ Matthew W. Sonsini

	Name:	 	Matthew W. Sonsini
	Title:	 	Chief Executive Officer, on behalf of
		 	Sobrato Family Holdings, LLC

 Address:
  [***] 

  

SIGNATURE PAGE TO AMENDED AND RESTATED
INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	 INVESTOR:

	
	 PH INVESTMENTS, LLC

		
	By:	 	 /s/ Melinda E. Barber

	Name:	 	Melinda E. Barber
	Title:	 	Managing Director

 Address:
  [***] 
 With a copy to:   [***] 

  

SIGNATURE PAGE TO AMENDED AND RESTATED
INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	 INVESTOR:

	
	 FIFTH AVENUE PRIVATE EQUITY 14 LLC

		
	By:	 	 /s/ Charles D. Bryceland

	Name:	 	Charles D. Bryceland
	Title:	 	Authorized Signatory

 Address:
  [***] 

  

SIGNATURE PAGE TO AMENDED AND RESTATED
INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	 INVESTOR:

	
	 FIFTH AVENUE PRIVATE EQUITY 15 LLC

		
	By:	 	 /s/ Charles D. Bryceland

	Name:	 	Charles D. Bryceland
	Title:	 	Authorized Signatory

 Address:
  [***] 

  

SIGNATURE PAGE TO AMENDED AND RESTATED
INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	 INVESTOR:

	
	 PORTLAND INVESTMENT – EP, LLC

		
	By:	 	 /s/ David Weden

	Name:	 	David Weden
	Title:	 	Authorized Signatory

 Address:
  [***] 
 With a copy to:   [***] 

 

			
	 PORTLAND INVESTMENT – PIA, LLC

		
	By:	 	 /s/ David Weden

	Name:	 	David Weden
	Title:	 	Authorized Signatory

 Address:   [***] 

With a copy to:   [***] 

  

SIGNATURE PAGE TO AMENDED AND RESTATED
INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

					
		 	INVESTOR:
		
		 	ZONE II HEALTHCARE HOLDINGS, LLC
		
		 	By: Farallon Capital Management, L.L.C., its Manager
			
		 	By:	 	
/s/ Thomas G. Roberts, Jr.             
        

		 	Name:	 	Thomas G. Roberts, Jr.
		 	Title:	 	Managing Member

 Address:   [***] 

For Notices:   [***] 

  

SIGNATURE PAGE TO AMENDED AND RESTATED
INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	CORMORANT PRIVATE HEALTHCARE FUND II, LP
	
	BY: Cormorant Private Healthcare GP II, LLC
		
	By:	 	 /s/ Bihua Chen

	Name:	 	Bihua Chen
	Title:	 	 Managing Member of the
GP

 Address:   [***] 

 

			
	CORMORANT GLOBAL HEALTHCARE MASTER FUND, LP
	
	BY: Cormorant Global Healthcare GP, LLC
		
	By:	 	 /s/ Bihua Chen

	Name:	 	Bihua Chen
	Title:	 	 Managing Member of the
GP

 Address:   [***] 

 

			
	CRMA SPV, LP
	
	BY: Cormorant Asset Management, LP
	
	Its: Attorney-In-Fact
		
	 By:
	 	 /s/ Bihua Chen

	Name:	 	Bihua Chen
	 Title:
	 	 CEO/Managing Member

 Address:   [***] 

Notice Address:   [***] 

  

SIGNATURE PAGE TO AMENDED AND RESTATED
INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	AGENT CAPITAL FUND I LP
	
	By: Agent Capital Fund I GP, LLC, its General Partner
		
	By:	 	 /s/ Geeta Vemuri

 
			
	Name:	 	Geeta Vemuri

 
			
	Title:	 	Managing Member

 Address:
  [***] 

  

SIGNATURE PAGE TO AMENDED AND RESTATED
INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	CITADEL MULTI-STRATEGY EQUITIES MASTER FUND LTD.
	
	By: Citadel Advisors, LLC, its portfolio manager
		
	By:	 	 /s/ Noah Goldberg

	Name: Noah Goldberg
	Title: Authorized Signatory

Notices: 
  

			
	Citadel Multi-Strategy Equities Master Fund Ltd.

Address:   [***] 

with a copy to: 

Address:   [***] 

  

SIGNATURE PAGE TO AMENDED AND RESTATED
INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	LOGOS OPPORTUNITIES FUND I, L.P.
	
	By: Logos Opportunities GP, LLC
	Its General Partner
		
	By:	 	 /s/ Arsani William

	Name:	 	Arsani William
	Title:	 	Manager

 Address:   [***] 

  

SIGNATURE PAGE TO AMENDED AND RESTATED
INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

					
		 	INVESTOR:
		
		 	REDMILE BIOPHARMA INVESTMENTS II, L.P.
		
		 	By: Redmile Biopharma Investments II (GP), LLC, its general partner
			
		 	By:	 	 /s/ Josh Garcia

		 	Name:	 	Josh Garcia
		 	Title:	 	CFO and Authorized Signatory

 Address:   [***] 

For Notices:   [***] 

  

SIGNATURE PAGE TO AMENDED AND RESTATED
INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

					
		 	INVESTOR:
		
		 	BERNARD COULIE AND BARBARA LEYMAN, AS TRUSTEES OF THE COULIE/LEYMAN FAMILY TRUST UNDER AGREEMENT DATED APRIL 20, 2018
			
		 	By:	 	 /s/ Bernard Coulie

		 	Name:	 	Bernard Coulie, M.D., Ph.D.
		 	Title:	 	Trustee

 Address:   [***] 

  

SIGNATURE PAGE TO AMENDED AND RESTATED
INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	Altamont Pharmaceutical Holdings, LLC
		
	By:	 	 /s/ Mark Pearson

	Name:	 	Mark Pearson
	Title:	 	CEO

 Address:   [***] 

  

SIGNATURE PAGE TO AMENDED AND RESTATED
INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	Mark Pearson IRA
		
	By:	 	 /s/ Mark Pearson

	Name:	 	Mark Pearson

 Address:   [***] 

  

SIGNATURE PAGE TO AMENDED AND RESTATED
INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	Fernando Rock and Carole Hayworth Living Trust
		
	By:	 	 /s/ Fernando Rock

	Name:	 	Fernando Rock
	Title:	 	Trustee

 Address:   [***] 

  

SIGNATURE PAGE TO AMENDED AND RESTATED
INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	Tulum Terra, LLC
		
	By:	 	 /s/ Arthur Leung

	Name:	 	Arthur Leung
	Title:	 	Managing Member

 Address:
  [***] 

  

SIGNATURE PAGE TO AMENDED AND RESTATED
INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	XIA BVBA
		
	By:	 	 /s/ Bart M.E. Van Hooland

	Name:	 	Bart M.E. Van Hooland
	Title:	 	Manager

 Address:   [***] 

  

SIGNATURE PAGE TO AMENDED AND RESTATED
INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	2017 FAN PIER FUND A, LLC
		
	By:	 	 /s/ David Henken

	Name:	 	David Henken
	Title:	 	Managing Member

 Address:
  [***] 

  

SIGNATURE PAGE TO AMENDED AND RESTATED
INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

	
	INVESTOR:
	
	 /s/ Johannes Hull

	Johannes Hull

 Address: 

  

SIGNATURE PAGE TO AMENDED AND RESTATED
INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	 /s/ Katerina Leftheris

	Katerina Leftheris

Address:   [***] 

  

SIGNATURE PAGE TO AMENDED AND RESTATED
INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	 /s/ Harold A. Chapman

	Harold A. Chapman, M.D.

Address:   [***] 

  

SIGNATURE PAGE TO AMENDED AND RESTATED
INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

					
	INVESTOR:
	
	EVE-IRENE LEPIST AND TOUFIGH GORDI
		
	By:	 	 /s/ Eve-Irene Lepist

	Name:	 	Eve-Irene Lepist
		
	By:	 	 /s/ Toufigh Gordi

	Name:	 	Toufigh Gordi

 Address:
  [***] 

  

SIGNATURE PAGE TO AMENDED AND RESTATED
INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

					
	INVESTOR:
	
	JOHN T. AND MEREDYTH J. LILLEJORD
		
	By:	 	 /s/ John T. Lillejord

	Name:	 	John T. Lillejord
		
	By:	 	 /s/ Meredyth J. Lillejord

	Name:	 	Meredyth J. Lillejord

Address:   [***] 

  

SIGNATURE PAGE TO AMENDED AND RESTATED
INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

					
	INVESTOR:
	
	BENJAMEN E. AND JULI M. KERN
		
	By:	 	 /s/ Benjamen E. Kern

	Name:	 	Benjamen E. Kern
		
	By:	 	 /s/ Juli M. Kern

	Name:	 	Juli M. Kern	 	

 Address:   [***] 

  

SIGNATURE PAGE TO AMENDED AND RESTATED
INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	 /s/ Rik Derynck

	Rik Derynck

 Address:
  [***] 

  

SIGNATURE PAGE TO AMENDED AND RESTATED
INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

					
		 	INVESTOR:
		
		 	 /s/ Benoit Dolfijn

		 	Benoit Dolfijn

 Address:   [***] 

  

SIGNATURE PAGE TO AMENDED AND RESTATED
INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

					
		 	INVESTOR:
		
		 	 /s/ Erica Park

		 	Erica Park

 Address:   [***] 

  

SIGNATURE PAGE TO AMENDED AND RESTATED
INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	 /s/ Mika K Derynck

	Mika K Derynck

Address:   [***] 

  

SIGNATURE PAGE TO AMENDED AND RESTATED
INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	 /s/ James E. Bates

	James E. Bates

Address:   [***] 

  

SIGNATURE PAGE TO AMENDED AND RESTATED
INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	 /s/ Karuga Kimani

	Karuga Kimani

Address:   [***] 

  

SIGNATURE PAGE TO AMENDED AND RESTATED
INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	 /s/ Chon Yoa

	Chon Yoa

 Address:
  [***] 

  

SIGNATURE PAGE TO AMENDED AND RESTATED
INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	 /s/ Sam Zucker

	Sam Zucker

 Address:
  [***] 

  

SIGNATURE PAGE TO AMENDED AND RESTATED
INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	 /s/ Kraig K. Anderson

	Kraig K. Anderson

Address:   [***] 

  

SIGNATURE PAGE TO AMENDED AND RESTATED
INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	 /s/ Deepa Rich

	Deepa Rich

 Address:
  [***] 

  

SIGNATURE PAGE TO AMENDED AND RESTATED
INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

					
		 	INVESTOR:
		
		 	 /s/ Craig McDonald

		 	Craig McDonald

 Address:   [***] 

  

SIGNATURE PAGE TO AMENDED AND RESTATED
INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	 /s/ Russell M. Lebovitz

	Russell M. Lebovitz

Address:   [***] 

  

SIGNATURE PAGE TO AMENDED AND RESTATED
INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	 /s/ Barbara Howes

	Barbara Howes

Address:   [***] 

  

SIGNATURE PAGE TO AMENDED AND RESTATED
INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

					
		 	INVESTOR:
		
		 	 /s/ Keith Cummings

		 	Keith Cummings

 Address:   [***] 

  

SIGNATURE PAGE TO AMENDED AND RESTATED
INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	 /s/ Kim Cummings

	Kim Cummings

 Address:
  [***] 

  

SIGNATURE PAGE TO AMENDED AND RESTATED
INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	VALIANCE HOLDINGS LIMITED

 
			
		
	By:	 	 /s/ Jan Pensaert

	Name:	 	Jan Pensaert
	Title:	 	Director

 Address:   [***] 

  

SIGNATURE PAGE TO AMENDED AND RESTATED
INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	 /s/ Colin Stephen Magowan

	Colin Stephen Magowan

Address:   [***] 

  

SIGNATURE PAGE TO AMENDED AND RESTATED
INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	 /s/ Fung Yam Ng

	Fung Yam Ng

 Address:
  [***] 

  

SIGNATURE PAGE TO AMENDED AND RESTATED
INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

					
		 	INVESTOR:
		
		 	THE MURPHY 2005 LIVING TRUST
			
		 	By:	 	 /s/ Edward B. Murphy

		 	Name:	 	Edward B. Murphy
		 	Title:	 	Trustee

 Address:   [***] 

  

SIGNATURE PAGE TO AMENDED AND RESTATED
INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

					
		 	INVESTOR:
		
		 	 /s/ Ken Imamura

		 	Ken Imamura

 Address:   [***] 

  

SIGNATURE PAGE TO AMENDED AND RESTATED
INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

					
		 	INVESTOR:
		
		 	THE SLOGER HULL FAMILY TRUST
			
		 	By:	 	 /s/ Johannes Hull

		 	Name:	 	Johannes Hull
		 	Title:	 	Trustee

 Address:   [***] 

  

SIGNATURE PAGE TO AMENDED AND RESTATED
INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

					
		 	INVESTOR:
		
		 	 /s/ Jonathan Bellini

		 	Jonathan Bellini

 Address:   [***] 

  

SIGNATURE PAGE TO AMENDED AND RESTATED
INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

					
		 	INVESTOR:
		
		 	 /s/ Marco A. Martinot

		 	Marco A. Martinot

 Address:   [***] 

  

SIGNATURE PAGE TO AMENDED AND RESTATED
INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
		 	INVESTOR:
		
		 	THE CHRISTA RAYMOND SEPARATE
PROPERTY REVOCABLE TRUST
		
		 	By: /s/ Christa
Raymond                                    
		 	Name: Christa Raymond
		 	Title: Trustee

 Address:   [***] 

  

SIGNATURE PAGE TO AMENDED AND RESTATED
INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
		 	INVESTOR:
		
		 	 /s/ Todd G. Sears

		 	Todd G. Sears

 Address:   [***] 

  

SIGNATURE PAGE TO AMENDED AND RESTATED
INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
		 	INVESTOR:
		
		 	 /s/ Don Kraft

		 	Don Kraft

 Address:   [***] 

  

SIGNATURE PAGE TO AMENDED AND RESTATED
INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
		 	INVESTOR:
		
		 	 /s/ Scott Turner

		 	Scott Turner

 Address:   [***] 

  

SIGNATURE PAGE TO AMENDED AND RESTATED
INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
		 	INVESTOR:
		
		 	CARLOS AND CYNTHIA HENRIQUEZ
		
		 	By: /s/ Carlos Henriquez                               
 
		 	Name: Carlos Henriquez
		
		 	By: /s/ Cynthia Henriquez                             
		 	Name: Cynthia Henriquez

 Address:   [***] 

  

SIGNATURE PAGE TO AMENDED AND RESTATED
INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

	
	INVESTOR:
	
	 /s/ Brenda Henriquez

	Brenda Henriquez

 Address:
  [***] 

  

SIGNATURE PAGE TO AMENDED AND RESTATED
INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

	
	INVESTOR:
	
	 /s/ Scarlet R. Hamrick

	Scarlet R. Hamrick

 Address:
  [***] 

  

SIGNATURE PAGE TO AMENDED AND RESTATED
INVESTORS’ RIGHTS AGREEMENT 

 SCHEDULE A 

Schedule of Investors 
  

			
	 Name
	  	 Number of Shares Held

	 Novartis Institutes for BioMedical Research, Inc.

[***]
 ATTN: [***]
	  	[***]
		
	 Third Rock Ventures III, L.P.
 [***]

Attn: [***]
 Email: [***] 
Phone: [***]
	  	[***]
		
	 Third Rock Ventures IV, L.P.
 [***]

Attn: [***]
 Email: [***] 
Phone: [***]
	  	[***]
		
	 Cowen Healthcare Investments II LP
 c/o Cowen
Advisors, LLC
 [***]
 Attn: [***]
	  	[***]
		
	 CHI EF II LP
 c/o Cowen Advisors, LLC

[***]
 Attn: [***]
	  	[***]
		
	 Mutual Fund Series Trust, on Behalf of Eventide Gilead Fund

[***]
 Attn: [***]

With a copy to:
 [***]

[***]
	  	[***]
		
	 Mutual Fund Series Trust, on Behalf of Eventide Healthcare & Life Sciences Fund

[***]
 Attn: [***]

With a copy to:
 [***]

[***]
	  	[***]

			
		
	 IST3 Manesse PE L.P.
 [***]

Attn: [***]
	  	[***]
		
	 Schroder Adveq cPl Global 2017-2019 C.V.

[***]
 Attn: [***]
	  	[***]
		
	 Schroder Adveq Technology IX S.C.S.,
 [***]

Attn: [***]
	  	[***]
		
	 Menlo Ventures XIV, L.P.
 [***]

Attn: [***]
	  	[***]
		
	 Menlo Entrepreneurs Fund XIV, L.P.
 [***]

Attn: [***]
	  	[***]
		
	 MMEF XIV, L.P.
 [***]

Attn: [***]
	  	[***]
		
	 Mauna Kea Limited
 [***]

Attn: [***]
 Email: [***] 

	  	[***]
		
	 Altamont Pharmaceutical Holdings, LLC
 [***]

Attn: [***]
	  	[***]
		
	 Fifth Avenue Private Equity 14 LLC
 [***]

Attn: [***]
 Email: [***] 

	  	[***]
		
	 Fifth Avenue Private Equity 15 LLC
 [***]

Attn: [***]
 Email: [***] 

	  	[***]

			
		
	 Harvard Management Private Equity Corporation

[***]
 Attn: [***]

Email: [***] 

	  	[***]
		
	 SCubed Capital, LLC
 [***]

Attn: [***]
 Please also copy [***]
	  	[***]
		
	 PH Investments, LLC
 [***]

Attn: [***]
 Email: [***] 
With a copy to: [***]
	  	[***]
		
	 Portland Investment - EP, LLC
 Partners
HealthCare Investment Office
 [***]
 Attn: [***]

Phone: [***]
 Email: [***] 
With a copy to: [***]
	  	[***]
		
	 Portland Investment - PIA, LLC
 Partners
HealthCare Investment Office
 [***]
 Attn: [***]

Phone: [***]
 Email: [***] 
With a copy to: [***]
	  	[***]
		
	 Sobrato Capital
 [***]

Attn: [***]
 Email: [***] 

	  	[***]
		
	 Katerina Leftheris
 [***]
	  	[***]
		
	 Erica Park
 [***]
	  	[***]

			
		
	 Chon Yoa
 [***]
	  	[***]
		
	 Karuga Kimani
 [***]
	  	[***]
		
	 Tulum Terra, LLC
 [***]
	  	[***]
		
	 Fernando Rock and Carole Hayworth Living Trust

[***]
	  	[***]
		
	 Deepa Rich
 [***]
	  	[***]
		
	 Eve-Irene Lepist and Toufigh Gordi

[***]
	  	[***]
		
	 Harold A. Chapman, M.D.
 [***]
	  	[***]
		
	 Xia bvba
 [***]
	  	[***]
		
	 James E. Bates
 [***]
	  	[***]
		
	 Benoit Dolfijn
 [***]
	  	[***]
		
	 Benjamen E. and Juli M. Kern
 [***]
	  	[***]
		
	 Russell M. Lebovitz
 [***]
	  	[***]
		
	 John T. and Meredyth J. Lillejord

[***]
	  	[***]
		
	 Kraig K. Anderson
 [***]
	  	[***]
		
	 Rik Derynck
 [***]
	  	[***]

			
		
	 Mika K Derynck
 [***]
	  	[***]
		
	 Craig McDonald
 [***]
	  	[***]
		
	 Sam Zucker
 [***]
	  	[***]
		
	 2017 Fan Pier Fund A, LLC
 [***]

Attn: [***]
	  	[***]
		
	 Bernard Coulie and Barbara Leyman, as Trustees of the

Coulie/Leyman Family Trust Under Agreement
 Dated April 20,
2018
 [***]
	  	[***]
		
	 Mark Pearson IRA
 [***]

Attn: [***]
	  	[***]
		
	 Johannes Hull
 [***]
	  	[***]
		
	 pH Pharma Co., Ltd.
 [***]

Attn: [***]
 Email: [***]

Phone: [***]
	  	[***]
		
	 David Morgans
 [***]
	  	[***]
		
	 Patrick Andre
 [***]
	  	[***]
		
	 Sharon E. Tetlow, as Trustee of Sharon E. Tetlow Trust

[***]
	  	[***]
		
	 Hari Kumar
 [***]
	  	[***]
		
	 Alandra Mosely
 [***]
	  	[***]

			
		
	 Redmile Biopharma Investments II, L.P.
 c/o
Redmile Group, LLC 
[***]
 Attn: [***]
 E-mail: [***]
	  	[***]
		
	 Zone II Healthcare Holdings, LLC
 c/o Farallon
Capital Management, L.L.C. 
[***]
 Attn: [***]
 E-mail: [***]
	  	[***]
		
	 Citadel Multi-Strategy Equities Master Fund Ltd.

c/o Citadel Advisors LLC
 [***]

Attention: [***]
	  	[***]
		
	 Cormorant Private Healthcare Fund II, LP

[***]
 Attn: [***]
	  	[***]
		
	 Cormorant Global Healthcare Master Fund, LP

[***]
 Attn: [***]
	  	[***]
		
	 CRMA SPV, LP
 [***]

Attn: [***]
	  	[***]
		
	 Logos Opportunities Fund I, L.P.
 [***]
	  	[***]
		
	 Agent Capital Fund I LP
 [***]

Attn: [***]
	  	[***]
		
	 Barbara Howes
 [***]
	  	[***]
		
	 Keith Cummings
 [***]
	  	[***]
		
	 Kim Cummings
 [***]
	  	[***]

			
		
	 Valiance Holdings Limited
 [***]
	  	[***]
		
	 Colin Stephen Magowan
 [***]
	  	[***]
		
	 Fung Yam Ng
 [***]
	  	[***]
		
	 The Murphy 2005 Living Trust
 [***]
	  	[***]
		
	 Ken Imamura
 [***]
	  	[***]
		
	 The Sloger Hull Family Trust
 [***]
	  	[***]
		
	 Jonathan Bellini
 [***]
	  	[***]
		
	 Marco A. Martinot
 [***]
	  	[***]
		
	 The Christa Raymond Separate Property Revocable Trust

[***]
	  	[***]
		
	 Todd G. Sears
 [***]
	  	[***]
		
	 Don Kraft
 [***]
	  	[***]
		
	 Scott Turner
 [***]
	  	[***]
		
	 Carlos and Cynthia Henriquez
 [***]
	  	[***]
		
	 Brenda Henriquez
 [***]
	  	[***]
		
	 Scarlet R. Hamrick
 [***]
	  	[***]EX-10.6

 Exhibit 10.6 

PLIANT THERAPEUTICS, INC. 

EXECUTIVE SEVERANCE PLAN 

1. Purpose. Pliant Therapeutics, Inc., a Delaware corporation (the “Company”) considers it essential to the best interests of
its stockholders to foster the continuous employment of key management personnel. The Board of Directors of the Company (the “Board”) recognizes, however, that, as is the case with many publicly-held corporations, the possibility of an
involuntary termination of employment, either before or after a Change in Control (as defined in Section 2 hereof), exists and that such possibility, and the uncertainty and questions that it may raise among management, may result in the
departure or distraction of management personnel to the detriment of the Company and its stockholders. Therefore, the Board has determined that the Pliant Therapeutics, Inc. Executive Severance Plan (the “Plan”) should be adopted to
reinforce and encourage the continued attention and dedication of the Company’s Covered Executives (as defined in Section 2 hereof) to their assigned duties without distraction. Nothing in this Plan shall be construed as creating an
express or implied contract of employment and nothing shall alter the “at will” nature of the Covered Executives’ employment with the Company. 

2. Definitions. The following terms shall be defined as set forth below: 

(a) “Accounting Firm” shall mean a nationally recognized accounting firm selected by the Company. 

(b) “Administrator” means the Board or the Compensation Committee of the Board. 

(c) “Base Salary” shall mean the higher of (i) the annual base salary in effect immediately prior to the Date of
Termination or (ii) the annual base salary in effect for the year immediately prior to the year in which the Date of Termination occurs. 

(d) “Cause” shall mean, and shall be limited to, the occurrence of any one or more of the following events: 

(i) the Covered Executive’s unauthorized use or disclosure of the Company’s confidential information or trade
secrets; 
 (ii) the Covered Executive’s material breach of any agreement between the Covered Executive and the Company;

 (iii) the Covered Executive’s material failure to comply with the Company’s written policies or rules; 

(iv) the Covered Executive’s gross negligence or willful misconduct in connection with the Covered Executive’s
performance of his/her duties to the Company; 

  
 1 

 (v) the Covered Executive’s continuing failure to perform assigned
duties after receiving written notification of the failure from the Company and, if curable, a period of thirty (30) days to cure such failure; 

(vi) the conviction of, indictment for or plea of nolo contendere by the Covered Executive to a felony or a crime involving
moral turpitude; or 
 (vii) the Covered Executive’s failure to cooperate in good faith with a governmental or internal
investigation of the Company or its directors, officers or employees, if the Company has requested the Covered Executive’s cooperation. 

(e) “Change in Control” shall mean a Sale Event, as defined in the Pliant Therapeutics, Inc. 2019 Stock Option and Incentive
Plan, as amended from time to time. 
 (f) “Change in Control Period” shall mean the period beginning on the date of a
Change in Control and ending on the one-year anniversary of the Change in Control. 
 (g)
“Code” shall mean the Internal Revenue Code of 1986, as amended. 
 (h) “Covered Executives” shall mean
Tier 1 Executive and those other employees designated by the Administrator in its sole discretion as the Tier 2 Executives, and, in each case, who meet the eligibility requirements set forth in Section 4 of the Plan. 

(i) “Date of Termination” shall mean the date that a Covered Executive’s employment with the Company (or any successor)
ends, which date shall be specified in the Notice of Termination. Notwithstanding the foregoing, a Covered Executive’s employment shall not be deemed to have been terminated solely as a result of the Covered Executive becoming an employee of
any direct or indirect successor to the business or assets of the Company. 
 (j) “Disability” shall mean the following: if
through any illness, injury, accident or condition of either a physical or psychological nature, the Covered Executive becomes unable to perform substantially all of his duties and responsibilities for a continuous period of sixteen
(16) consecutive weeks or for any twenty-six (26) weeks within a fifty-two (52) week period.
Determinations as to whether Covered Executive is Disabled shall be made by a physician selected by the Board or its insurers and acceptable to the Covered Executive or the Covered Executive’s legal representative, such agreement as to
acceptability not to be unreasonably withheld or delayed. 
 (k) “Good Reason” shall mean that the Covered Executive has
complied with the “Good Reason Process” following the occurrence of any of the following events: 
 (i) a material
diminution in the Covered Executive’s annual base salary other than across the board decreases in annual base salary similarly affecting all executives of the Company; 

(ii) the Company requiring the Covered Executive to relocate (other than for travel incident to the Covered Executive’s
performance of his or her duties on behalf of the Company) a distance of more than fifty (50) miles from the Covered Executive’s current principal place of business; or 

  
 2 

 (iii) any material diminution in the Covered Executive’s position,
responsibilities, authority or duties. 
 For purposes of Section 2(k)(iii), a change in the reporting relationship, or a change in a title will not,
by itself, be sufficient to constitute a material diminution of responsibilities, authority or duty. 
 (l) “Good Reason
Process” shall mean: 
 (i) the Covered Executive reasonably determines in good faith that a “Good Reason”
condition has occurred; 
 (ii) the Covered Executive notifies the Company in writing of the first occurrence of the Good
Reason condition within sixty (60) days of the first occurrence of such condition; 
 (iii) the Covered Executive
cooperates in good faith with the Company’s efforts, for a period of not less than thirty (30) days following such notice (the “Cure Period”), to remedy the condition; 

(iv) notwithstanding such efforts, the Good Reason condition continues to exist following the Cure Period; and 

(v) the Covered Executive terminates his or her employment and provides the Company with a Notice of Termination with respect
to such termination, each within sixty (60) days after the end of the Cure Period. 
 If the Company cures the Good Reason condition
during the Cure Period, Good Reason shall be deemed not to have occurred. 
 (m) “Notice of Termination” shall mean a
written notice which shall indicate the specific termination provision in this Plan relied upon for the termination of a Covered Executive’s employment and the Date of Termination. 

(n) “Participation Agreement” shall mean an agreement between a Covered Executive and the Company that
acknowledges the Covered Executive’s participation in the Plan.  
 (o) “Qualified Termination
Event” shall mean (i) a termination of the Covered Executive’s employment by the Company other than for Cause, death or Disability or (ii) the Covered Executive’s resignation from the Company for Good Reason. 

(p) “Restrictive Covenants Agreement” shall mean the Employee Confidential Information and Inventions Assignment Agreement or
similar agreement entered into between the Covered Executive and the Company. 
 (q) “Tier 1 Executive” shall mean the
Company’s Chief Executive Officer. 

  
 3 

 (r) “Tier 2 Executives” shall mean the individuals designated as such by
the Administrator and who are listed in Exhibit A, attached hereto, as such exhibit is amended by the Administrator from time to time. 

3. Administration of the Plan.  

(a) Administrator. The Plan shall be administered by the Administrator. 

(b) Powers of Administrator. The Administrator shall have all powers necessary to enable it properly to carry out its duties with
respect to the complete control of the administration of the Plan. Not in limitation, but in amplification of the foregoing, the Administrator shall have the power and authority in its discretion to: 

(i) construe the Plan to determine all questions that shall arise as to interpretations of the Plan’s provisions; 

(ii) determine which individuals are and are not Covered Executives, designate an individual as a Tier 2 Executive, determine
the benefits to which any Covered Executives may be entitled, the eligibility requirements for participation in the Plan and all other matters pertaining to the Plan; 

(iii) adopt amendments to the Plan which are deemed necessary or desirable to comply with all applicable laws and regulations,
including but not limited to Code Section 409A and the guidance thereunder; 
 (iv) make all determinations it deems
advisable for the administration of the Plan, including the authority and ability to delegate administrative functions to a third party; 

(v) decide all disputes arising in connection with the Plan; and 

(vi) otherwise supervise the administration of the Plan. 

(c) All decisions and interpretations of the Administrator shall be binding on all persons, including the Company and Covered Executives. 

4. Eligibility. All Covered Executives who have executed and submitted to the Company a Participation Agreement, and satisfied such
other requirements as may be determined by the Administrator, are eligible to participate in the Plan. The Administrator may determine at any time that a Covered Executive should no longer be designated as such as a result of a material change in
such Covered Executive’s role, and such individual shall cease to be eligible to participate in the Plan upon the Administrator taking action by resolution to update the applicable Exhibit hereto. 

5. Termination Benefits Generally. In the event a Covered Executive’s employment with the Company is terminated for any reason, the
Company shall pay or provide to the Covered Executive any earned but unpaid salary, unpaid expense reimbursements in accordance with Company policy, accrued but unused vacation or leave entitlement, and any vested benefits

  
 4 

 
the Covered Executive may have under any employee benefit plan of the Company in accordance with the terms and conditions of such employee benefit plan (collectively, the “Accrued
Benefits”), within the time required by law but in no event more than sixty (60) days after the Date of Termination. 
 6.
Termination Not in Connection with a Change in Control. In the event of a termination of the Covered Executive’s employment by the Company, other than for Cause, death or Disability, at any time other than during the Change in Control
Period, with respect to such Covered Executive, in addition to the Accrued Benefits, subject to his or her execution of a separation agreement in a form and manner satisfactory to the Company containing, among other provisions, a general release of
claims in favor of the Company and related persons and entities, confidentiality, return of property, and non-disparagement provisions and reaffirmation of the Restrictive Covenants Agreement (the
“Separation Agreement and Release”) and the Separation Agreement and Release becoming irrevocable, all within the time period set forth in the Separation Agreement and Release but in no event more than sixty (60) days after the Date
of Termination, and subject to the Covered Executive complying with the Separation Agreement and Release, the Company shall: 
 (a) pay the
Covered Executive an amount equal to the sum of (i) twelve (12) months’ Base Salary for the Tier 1 Executive and nine (9) months’ Base Salary for each Tier 2 Executive (ii) plus the Covered Executive’s annual target
bonus in effect immediately prior to the Date of Termination, prorated as of the Covered Executive’s Date of Termination; and 
 (b) if
the Covered Executive was participating in the Company’s group health plan immediately prior to the Date of Termination and elects COBRA health continuation, then the Company shall pay to the Covered Executive a monthly cash payment in an
amount equal to the monthly employer contribution that the Company would have made to provide health insurance to the Covered Executive if the Covered Executive had remained employed by the Company, based on the premiums as of the Date of
Termination, until the earlier of (i) twelve (12) months for the Tier 1 Executive and nine (9) months for each Tier 2 Executive after the Date of Termination or (ii) the date on which the Covered Executive obtains other employment.

 The amounts payable under Section 6(a) and (b), as applicable, shall be paid out in substantially equal installments in accordance with the
Company’s payroll practice over twelve (12) months for the Tier 1 Executive and over nine (9) months for each Tier 2 Executive within sixty (60) days after the Date of Termination; provided, however, that if the 60-day period begins in one calendar year and ends in a second calendar year, the amounts shall be paid in the second calendar year no later than the last day of such 60-day
period; provided further, that the initial payment shall include a catch-up payment to cover amounts retroactive to the day immediately following the Date of Termination. Each payment pursuant to this Plan is
intended to constitute a separate payment for purposes of Treasury Regulation Section 1.409A-2(b)(2). 

7. Termination in Connection with a Change in Control. In the event a Qualified Termination Event occurs within the Change in Control
Period, then with respect to such Covered Executive, in addition to the Accrued Benefits, subject to his or her execution and non-revocation of the Separation Agreement and Release, all within the time period
set forth in the Separation Agreement and Release, but in no event more than sixty (60) days after the Date of Termination, the Company shall: 

  
 5 

 (a) cause 100% of the outstanding and unvested equity awards with time-based vesting held by
the Covered Executive to immediately become fully vested, exercisable or nonforfeitable as of the Date of Termination; provided, that the performance conditions applicable to any outstanding and unvested equity awards subject to performance
conditions will be deemed satisfied at the target level specified in the terms of the applicable award agreement. Notwithstanding the foregoing, in the event of a Change in Control where the
parties to such Change in Control do not provide for the assumption, continuation or substitution of equity awards of the Company, any and all outstanding and unvested equity awards held by the Covered Executive shall be subject to Section 3(d)
of the Company’s 2019 Stock Option and Incentive Plan, as amended from time to time; 
 (b) pay to the Covered Executive an amount equal
to the sum of (i) 150% of Base Salary for the Tier 1 Executive and 100% of Base Salary for each Tier 2 Executive plus (ii) 150% for the Tier 1 Executive and 100% for each Tier 2 Executive, of the Covered Executive’s annual target bonus in
effect immediately prior to the Qualified Termination Event (or the Covered Executive’s target bonus in effect immediately prior to the Change in Control, if higher); and 

(c) if the Covered Executive was participating in the Company’s group health plan immediately prior to the Date of Termination and elects
COBRA health continuation, then the Company shall pay to the Covered Executive a lump sum cash payment in an amount equal to the monthly employer contribution that the Company would have made to provide health insurance to the Covered Executive if
the Covered Executive had remained employed by the Company for eighteen (18) months for the Tier 1 Executive and twelve (12) months for each Tier 2 Executive after the Date of Termination, based on the premiums as of the Date of
Termination. 
 The amounts payable under Section 7(b) and (c), as applicable, shall be paid out in a lump sum within sixty (60) days after the
Date of Termination; provided, however, that if the 60-day period begins in one calendar year and ends in a second calendar year, the amounts shall be paid in the second calendar year no later than the last
day of the 60-day period. For the avoidance of doubt, the severance pay and benefits provided in this Section 7 shall apply in lieu of, and expressly supersede, the provisions of Section 6 and no
Covered Executive shall be entitled to the severance pay and benefits under both Section 6 and 7 hereof. 
 8. Additional
Limitation. 
 (a) Anything in this Plan to the contrary notwithstanding, in the event that the amount of any compensation, payment or
distribution by the Company to or for the benefit of the Covered Executive, whether paid or payable or distributed or distributable pursuant to the terms of this Plan or otherwise, calculated in a manner consistent with Section 280G of the Code
and the applicable regulations thereunder (the “Aggregate Payments”), would be subject to the excise tax imposed by Section 4999 of the Code, then the Aggregate Payments shall be reduced (but not below zero) so that the sum of all of
the Aggregate Payments shall be $1.00 less than the amount at which the Covered Executive becomes subject to the excise tax imposed by Section 4999 of 

  
 6 

 
the Code; provided that such reduction shall only occur if it would result in the Covered Executive receiving a higher After Tax Amount (as defined below) than the Covered Executive would receive
if the Aggregate Payments were not subject to such reduction. In the event of such reduction, the Aggregate Payments shall be reduced in the following order, in each case, in reverse chronological order beginning with the Aggregate Payments that are
to be paid the furthest in time from consummation of the transaction that is subject to Section 280G of the Code: (i) cash payments not subject to Section 409A of the Code; (ii) cash payments subject to Section 409A of the
Code; (iii) equity-based payments and acceleration; and (iv) non-cash forms of benefits; provided that in the case of all the foregoing Aggregate Payments all amounts or payments that are not subject
to calculation under Treas. Reg. §1.280G-1, Q&A-24(b) or (c) shall be reduced before any amounts that are subject to calculation under Treas. Reg. §1.280G-1, Q&A-24(b) or (c). 
 (b) For purposes of this
Section 8, the “After Tax Amount” means the amount of the Aggregate Payments less all federal, state, and local income, excise and employment taxes imposed on the Covered Executive as a result of the Covered Executive’s receipt
of the Aggregate Payments. For purposes of determining the After Tax Amount, the Covered Executive shall be deemed to pay federal income taxes at the highest marginal rate of federal income taxation applicable to individuals for the calendar year in
which the determination is to be made, and state and local income taxes at the highest marginal rates of individual taxation in each applicable state and locality, net of the maximum reduction in federal income taxes (if any) which could be obtained
from deduction of such state and local taxes. 
 (c) The determination as to whether a reduction in the Aggregate Payments shall be made
pursuant to Section 8(a) shall be made by the Accounting Firm, which shall provide detailed supporting calculations both to the Company and the Covered Executive within fifteen (15) business days of the Date of Termination, if applicable,
or at such earlier time as is reasonably requested by the Company or the Covered Executive. Any determination by the Accounting Firm shall be binding upon the Company and the Covered Executive. 

9. Restrictive Covenants Agreement. 
 As a
condition to participating in the Plan, each Covered Executive shall continue to comply with the terms and conditions contained in the Restrictive Covenants Agreements or similar agreement entered into between the Covered Executive and the Company
and such other agreement(s) as designated in the applicable Participation Agreement. If a Covered Executive has not entered into a Restrictive Covenants Agreement or similar agreement with the Company, he or she shall enter into such agreement prior
to participating in the Plan.  
 10. Withholding. All payments made by the
Company under this Plan shall be subject to any tax or other amounts required to be withheld by the Company under applicable law. 

  
 7 

 11. Section 409A. 

(a) Anything in this Plan to the contrary notwithstanding, if at the time of the Covered Executive’s “separation from service”
within the meaning of Section 409A of the Code, the Company determines that the Covered Executive is a “specified employee” within the meaning of Section 409A(a)(2)(B)(i) of the Code, then to the extent any payment or benefit
that the Covered Executive becomes entitled to under this Plan would be considered deferred compensation subject to the twenty (20) percent additional tax imposed pursuant to Section 409A(a) of the Code as a result of the application of
Section 409A(a)(2)(B)(i) of the Code, such payment shall not be payable and such benefit shall not be provided until the date that is the earlier of (i) six (6) months and one (1) day after the Covered Executive’s separation from
service, or (ii) the Covered Executive’s death. If any such delayed cash payment is otherwise payable on an installment basis, the first payment shall include a catch-up payment covering amounts that
would otherwise have been paid during the six-month period but for the application of this provision, and the balance of the installments shall be payable in accordance with their original schedule. 

(b) The parties intend that this Plan will be administered in accordance with Section 409A of the Code and that all amounts payable
hereunder shall be exempt from the requirements of such section as a result of being “short term deferrals” for purposes of Section 409A of the Code to the greatest extent possible. To the extent that any provision of this Plan is not
exempt from Section 409A of the Code and ambiguous as to its compliance with Section 409A of the Code, the provision shall be read in such a manner to comply with Section 409A of the Code. Each payment pursuant to this Plan is
intended to constitute a separate payment for purposes of Treasury Regulation Section 1.409A-2(b)(2). The parties agree that this Plan may be amended, as reasonably requested by either party, and as may
be necessary to fully comply with Section 409A of the Code and all related rules and regulations in order to preserve the payments and benefits provided hereunder without additional cost to either party. 

(c) To the extent that any payment or benefit described in this Plan constitutes “non-qualified
deferred compensation” under Section 409A of the Code, and to the extent that such payment or benefit is payable upon the Covered Executive’s termination of employment, then such payments or benefits shall be payable only upon the
Covered Executive’s “separation from service.” The determination of whether and when a separation from service has occurred shall be made in accordance with the presumptions set forth in Treasury Regulation Section 1.409A-1(h). 
 (d) All in-kind benefits provided and
expenses eligible for reimbursement under this Plan shall be provided by the Company or incurred by the Covered Executive during the time periods set forth in this Plan. All reimbursements shall be paid as soon as administratively practicable, but
in no event shall any reimbursement be paid after the last day of the taxable year following the taxable year in which the expense was incurred. The amount of in-kind benefits provided or reimbursable expenses
incurred in one taxable year shall not affect the in-kind benefits to be provided or the expenses eligible for reimbursement in any other taxable year (except for any lifetime or other aggregate limitation
applicable to medical expenses). Such right to reimbursement or in-kind benefits is not subject to liquidation or exchange for another benefit. 

(e) The Company makes no representation or warranty and shall have no liability to the Covered Executive or any other person if any provisions
of this Plan are determined to constitute deferred compensation subject to Section 409A of the Code but do not satisfy an exemption from, or the conditions of, such Section. 

  
 8 

 12. Notice and Date of Termination. 

(a) Notice of Termination. A termination of the Covered Executive’s employment shall be communicated by Notice of Termination from
the Company to the Covered Executive or vice versa in accordance with this Section 12. 
 (b) Notice to the Company. Any notices,
requests, demands, and other communications provided for by this Plan shall be sufficient if in writing and delivered in person or sent by registered or certified mail, postage prepaid, to a Covered Executive at the last address the Covered
Executive has filed in writing with the Company, or to the Company at the following physical or email address: 
 Pliant Therapeutics, Inc.

 Attention: Chief Human Resource Officer 

260 Littlefield Avenue 
 South San
Francisco, CA 94080 
 BHowes@pliantrx.com 

13. No Mitigation. The Covered Executive is not required to seek other employment or to attempt in any way to reduce any amounts payable
to the Covered Executive by the Company under this Plan. 
 14. Benefits and Burdens. This Plan shall inure to the benefit of and be
binding upon the Company and the Covered Executives, their respective successors, executors, administrators, heirs and permitted assigns. In the event of a Covered Executive’s death after a termination of employment but prior to the completion
by the Company of all payments due to him or her under this Plan, the Company shall continue such payments to the Covered Executive’s beneficiary designated in writing to the Company prior to his or her death (or to his or her estate, if the
Covered Executive fails to make such designation). 
 15. Enforceability. If any portion or provision of this Plan shall to any extent
be declared illegal or unenforceable by a court of competent jurisdiction, then the remainder of this Plan, or the application of such portion or provision in circumstances other than those as to which it is so declared illegal or unenforceable,
shall not be affected thereby, and each portion and provision of this Plan shall be valid and enforceable to the fullest extent permitted by law. 

16. Waiver. No waiver of any provision hereof shall be effective unless made in writing and signed by the waiving party. The failure of
any party to require the performance of any term or obligation of this Plan, or the waiver by any party of any breach of this Plan, shall not prevent any subsequent enforcement of such term or obligation or be deemed a waiver of any subsequent
breach. 

  
 9 

 17. Non-Duplication of Benefits and Effect on
Other Plans. Notwithstanding any other provision in the Plan to the contrary, the benefits provided hereunder shall be in lieu of any other severance payments and/or benefits provided by the Company, including any such payments and/or benefits
pursuant to an employment agreement or offer letter between the Company and the Covered Executive, other than as provided in Section 3(d) of the Company’s 2019 Stock Option and Incentive Plan, as amended from time to time; provided, that in the
event the Covered Executive is party to an agreement or other arrangement with the Company that provides greater benefits than set forth in this Plan, such employee shall be entitled to receive the payments or benefits under such other agreement or
arrangement and shall not be eligible to receive any payments or benefits under this Plan and the defined terms in the Plan shall supersede the corresponding defined terms or other similar terms in such other agreement or arrangement.  

18. No Contract of Employment. Nothing in this Plan shall be construed as giving any Covered Executive any right to be retained in the
employ of the Company or shall affect the terms and conditions of a Covered Executive’s employment with the Company. 
 19. Amendment
or Termination of Plan. The Company may amend or terminate this Plan at any time or from time to time, but no such action shall adversely affect the rights of any Covered Executive without the Covered Executive’s written consent. 

20. Governing Law. This Plan shall be construed under and be governed in all respects by the laws of the State of Delaware, without
giving effect to the conflict of laws principles. 
 21. Obligations of Successors. In addition to any obligations imposed by law upon
any successor to the Company, any successor (whether direct or indirect, by purchase, merger, consolidation or otherwise) to all or substantially all of the business or assets of the Company shall expressly assume and agree to perform this Plan in
the same manner and to the same extent that the Company would be required to perform if no such succession had taken place. 
 22.
Effectiveness and Term. The Executive Severance Plan is effective as of [______]. 

  
 10 

 Exhibit A 

Tier 2 Executives 
  

			
	 Individual
	 	 Title

		 	
		 	
		 	
		 	

  
 11

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00309-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00309-of-00352.parquet"}]]